Full Report

Industry — Pharmaceutical Contract Manufacturing for Sterile Injectables (India)

Onyx Biotec is not a drug company. It is a toll factory that fills sterile water and dry-powder antibiotics into ampoules and vials for brand-owners like Sun Pharma, Mankind and Aristo, under their labels. The arena has three tightly linked sub-industries: (i) sterile-water-for-injection (SWFI/WFI) — the diluent injected with most parenterals; (ii) dry-powder injectables, dominated by cephalosporin antibiotics; and (iii) the broader Indian pharmaceutical CDMO outsourcing pool. SWFI is a commodity volume business priced in paisa per ampoule; cephalosporin DPIs are a low-growth therapeutic with regulatory complexity; the CDMO wrapper gives a small Solan-based manufacturer access to top-20 Indian pharma demand. An SME pharma CDMO is a fixed-cost factory disguised as a manufacturer of branded products — capacity utilisation, not pricing, runs the P&L.

Takeaway: Onyx sits in Layer 2 — the conversion layer — selling capacity to Layer 3 brand-owners who keep the brand margin. The pricing power lives upstream of Onyx (in commoditised inputs) and downstream of Onyx (in branded retail), not in the layer Onyx occupies.

How This Industry Makes Money

A pharma CDMO charges its customer either a per-unit conversion fee (₹ per ampoule / vial filled, where the CDMO buys the raw materials) or a loan-licensing fee (a tolling charge where the customer ships in API and packaging). Onyx operates predominantly on the per-unit conversion model: it procures glass, granules and API, fills the product to client specifications, and bills against client purchase orders. The unit economics look more like a high-utilisation factory than a pharma brand.

Takeaway: The profit pool is bottom-heavy at the brand and API ends, and narrowest in the SME conversion segment where Onyx lives. The single biggest swing factor in this layer is capacity utilisation — the same ampoule line earns very different cents on the rupee at 50% vs 85% load. Sub-scale players that cannot hold ≥70% utilisation typically print mid-single-digit EBITDA margins; large CDMOs at 75-85% utilisation print 20%+.

Cost structure is heavily fixed once you take possession of a Form-Fill-Seal (FFS) line, a multi-column distillation plant and a cleanroom. Raw materials (LDPE granules, glass vials, butyl bungs, API powder, flip-off seals) are ~55-65% of cost of goods for a typical sterile CMO; conversion (labour, power, validation, depreciation, QC) is the remaining 35-45%. Working capital is heavy: top-10 customers can take 90-120 days to pay because brand-owners use CDMOs as a credit line. The "hidden line" in every CDMO P&L is the cost of regulatory compliance: WHO-GMP, USFDA inspections, EU-GMP audits, and now India's Revised Schedule M each carry six- to seven-figure capex tickets that are absorbed by the manufacturer, not the brand-owner.

Bargaining power asymmetry is severe. A top-10 customer that represents 10-20% of a CDMO's revenue can switch vendors with 60-90 days' notice. The reverse is not true — losing one customer in 100 dents your year. This is why client concentration is the single most-watched line in the segment.

Demand, Supply, and the Cycle

Underlying volume growth in Indian pharma is structural, not cyclical: 6-8% CAGR FY18-FY23, 9-11% expected for FY24 per ICRA, driven by lifestyle disease prevalence, expanding hospital infrastructure (~160,000 new beds per year per McKinsey), Jan Aushadhi expansion (10,607 outlets, target 25,000), and the Production Linked Incentive (PLI) scheme. The injectable sub-segment grows faster than oral — global dry powder injectables are projected to expand from $12.5B in 2023 to $22.8B by 2032 (~6.9% CAGR per dataintelo); the global Water-for-Injection market is projected from $30.5B in 2024 to $71.7B by 2035 (~8.0% CAGR per Transparency Market Research).

But the cycle in this layer is utilisation-driven, not price-driven.

Takeaway: For a sub-scale sterile CDMO, the cycle hits in this order: (1) end-customer demand softens → (2) brand-owner cuts purchase orders → (3) plant utilisation drops → (4) fixed-cost absorption collapses → (5) raw material cost-of-goods ratio rises → (6) receivable days stretch → (7) EBITDA margin halves before revenue moves much. The 2022 → 2023 SWI demand reversal at Onyx (revenue down 12%, EBITDA margin from 12.6% to 11.3%, capacity utilisation from 69.2% to 62.9%) is a textbook example: the trigger was the post-COVID end of vaccine-dilutant demand, not pricing.

Competitive Structure

The Indian pharmaceutical industry has 3,000 drug companies and ~10,500 manufacturing units across 60 therapeutic categories. The sterile-injectable contract-manufacturing pocket Onyx plays in is fragmented and price-competitive, not winner-take-most. The IPO prospectus describes the segment in management's own words as "highly competitive and fragmented." A handful of consolidated CDMOs at the top compete with hundreds of state-level WHO-GMP units at the bottom; in the middle sits a long tail of NSE SME-scale operators like Onyx.

Takeaway: The competitive set is not a clean ladder. The same brand-owners (Sun, Mankind, Aristo, Macleods) that are Onyx's top revenue customers also run their own internal injectable capacity and outsource only their peak load — making them both customer and latent competitor. The most economically dangerous competitor is not a peer like Akums but the next un-listed Solan SME offering the same SWFI ampoule at ₹0.10-0.20 less per unit. There is no defensible moat at the SWFI commodity end; the only moats are scale economics (Akums-level) or therapeutic complexity (Cohance-level), neither of which an SME-scale Solan site possesses.

Regulation, Technology, and Rules of the Game

Regulation, not technology, is the dominant external force. India's pharmaceutical regulatory framework changed materially in the past 24 months in ways that disproportionately affect SME sterile manufacturers.

Takeaway: Schedule M is the single regulation a reader of the rest of this report should keep in mind. Effective 31 December 2025 for sub-₹250 Cr manufacturers, it forces every Indian pharma SME — including every Solan competitor of Onyx — either to invest in PQS/QRM/cleanroom upgrades or to file a Form A and risk eventual closure. The longer-term effect is a structural contraction in the SME tail of Indian pharma manufacturing, which is supportive for compliant CDMOs that can absorb the displaced volume. The downside is that the same upgrade capex (HVAC, water systems, environment monitoring, electronic batch records) competes for cash that an SME like Onyx might otherwise spend on new product lines.

On the technology side, this is a mature small-molecule sterile space — Form-Fill-Seal ampoules, aseptic vial filling, multi-column distillation — not the biologics or cell-and-gene frontier. Innovation is incremental: high-speed cartoning, 21 CFR-compliant machines, large-volume parenteral capability, lyophilisation. None of these create a moat; they keep a player in the bid set.

The Metrics Professionals Watch

Takeaway: For a sterile CDMO, the three numbers that matter most in any given period are capacity utilisation, customer concentration, and debtor turnover. EBITDA margin is downstream of those three. ROCE is downstream of EBITDA margin and asset intensity. A reader who tracks only those three leading indicators will know about a turning point one to two quarters before it shows in earnings.

Where Onyx Biotec Limited Fits

Takeaway: Onyx is an SME-scale CDMO with table-stakes regulatory standing (WHO-GMP), heavy customer concentration (top-10 ≈ 94%), single-site geography risk, no regulated-market export optionality, and a recent (FY26) collapse into operating loss as Unit I utilisation slipped below 60%. The "industry backdrop" for Onyx is therefore mixed: the secular tailwind in Indian injectable contract manufacturing exists and is real, but Onyx's ability to capture it is constrained by scale, accreditation breadth, and customer-side bargaining power.

What to Watch First

The seven signals below are the fastest tells on whether the industry backdrop for Onyx is turning supportive or hostile. Each is observable in routine filings or accessible public data, so a reader can update the view between annual reports.

Know the Business — Onyx Biotec Limited

Onyx is a single-site fixed-cost factory that converts glass, plastic, API powder and distilled water into ampoules and vials for ~100 Indian pharma brand-owners — paid per unit filled, not per drug sold. The whole P&L is gated by one variable: how full the two Solan lines are running. The market currently prices this at roughly book value (~₹58 Cr market cap vs ₹55 Cr equity, P/B 1.05×). The decision-relevant question is not whether earnings will recover from the FY26 loss, but whether ROCE can stay above the cost of capital for long enough to justify any premium to replacement value.

1. How This Business Actually Works

Onyx charges a per-unit conversion fee (₹ per ampoule or vial filled) and books the raw-material pass-through as revenue. A ₹0.10 swing in conversion fee per SWFI ampoule on 230 million units a year is ₹2.3 Cr of operating profit — roughly two-thirds of FY26's entire operating profit. That is why this is a volume game pretending to be a pharma business. The two units run different economics: Unit I (sterile water, FFS ampoules, capacity 638,889/day) is the high-volume commodity engine; Unit II (cephalosporin dry-powder injections and dry syrups, capacity 40,000 + 26,667/day) is the higher-realisation product attempting to ramp post WHO-GMP certification in May 2024.

The bargaining-power asymmetry is the single biggest fact in this business. The top-10 customers that paid 71% of Onyx's FY24 revenue (top-5 = 51%) are themselves multi-thousand-crore pharma companies — Sun Pharma alone is ~1,000× larger by revenue. They can switch ampoule vendors in 60-90 days; Onyx cannot switch them. The Solan SME competitor 30 km down the road offers the same ampoule at a few paise less and runs the same WHO-GMP file. The two ways out are (a) scale to Akums-level breadth across 30+ dosage forms, or (b) acquire EU-GMP/USFDA status that opens regulated export pools. Onyx has done neither.

About 25-35% of the cost base is fixed once the cleanroom and FFS line are commissioned. That is the operating-leverage equation: a 10-point swing in utilisation moves OPM by roughly 4-6 percentage points. FY26 is the live demonstration — revenue grew 12% to ₹69.5 Cr but operating profit collapsed two-thirds because employee cost, depreciation and other opex stepped up with Unit II ramp while utilisation lagged.

2. The Playing Field

The peer set shows two clusters and one outlier. Pure-play scale CDMOs (Innova, Senores) earn 15% ROCE at 15-27% OPM. Branded-plus-CMO hybrids (JB Chem, Cohance) trade at premium multiples because the branded layer earns 25-30% margins regardless of plant utilisation. Akums sits in the middle — scale CDMO at lower margin but real ROCE. Onyx is the outlier on every dimension that matters: 1.1% ROCE is roughly one-thirteenth of the peer median, and the P/B at 1.05x already reflects this — the company trades at less than half the price-to-book of Akums and around an eighth of JB Chem's. The lesson is not that Onyx is cheap; it is that the market has correctly priced an unproven sub-scale CDMO at scrap-plus-working-capital value while peers are priced on demonstrated capital efficiency.

The competitive landscape is even harsher than this table suggests. Onyx's RHP names its top customers as Hetero, Mankind, Sun Pharma, Aristo, Macleods, Akums itself, and Reliance Life Sciences — every one of these companies either runs its own injectable lines or buys from larger CDMOs at better prices. The closest economic substitute is not the listed peer set but the ~1,000 unlisted Solan/Baddi WHO-GMP SMEs that compete at the SWFI ampoule end. Schedule M (effective 31 December 2025 for sub-₹250 Cr units) should thin that tail and is the single meaningful structural tailwind for compliant CDMOs like Onyx — but only if the displaced volume is large enough to push Onyx's utilisation past 75%, which has not yet happened.

3. Is This Business Cyclical?

This is not a macro-cyclical business in the way a steel or chemical company is. The cycle is utilisation-driven and customer-specific. The two recent regime changes prove the point. FY22→FY23 saw revenue fall 12% (₹44.9 Cr → ₹39.5 Cr) and OPM compress only 150 bps — that was the post-COVID end of vaccine-dilutant SWFI demand and the textbook example of a customer-order reset in this layer. FY26 looks different but works the same way: revenue rose 12% on Unit II ramp, but operating profit fell 67% (₹10.4 Cr → ₹3.4 Cr) because raw-material cost-of-goods absorbed a higher mix shift before pricing caught up, and fixed costs (D&A flat at ₹3.05 Cr, employee cost stepping up) stayed on the books regardless.

The order is the lesson. A reader who tracks only debtor days and Unit I utilisation will know about a margin reset one to two half-years before it hits the bottom line. The H1 FY26 print (net loss ₹0.9 Cr on ₹34.6 Cr revenue) was already the warning that the full-year FY26 result would be a write-off; the consensus narrative of "Unit II ramp = margin expansion" was wrong by the time the September 2025 print arrived.

4. The Metrics That Actually Matter

The three metrics that matter most are capacity utilisation, customer concentration, and debtor days — in that order. Every other number is downstream. EBITDA margin is the consequence of utilisation; net income is the consequence of EBITDA margin minus depreciation; ROCE is the consequence of net income relative to a near-fixed capital base. The mistake an analyst will make on this name is to anchor on revenue growth (the FY26 revenue print of ₹69.5 Cr looked fine) instead of margin and working-capital trajectory (the cash conversion cycle has nearly tripled from 51 days in FY22 to 119 in FY26).

ROCE was approaching peer-respectable levels (12.85% in FY24, 12.16% in FY25) before falling off a cliff in FY26 — a single-year collapse of more than 11 percentage points. A peer like Innova posts 15% ROCE consistently because its cost base is amortised across many more dosage forms and customers. The FY26 print tells you that the prior two years were not the new normal; they were the IPO-window peak before Unit II's depreciation and ramp costs collided with a soft revenue mix.

5. What Is This Business Worth?

The right lens here is price-to-book against trailing ROE, plus a tangible-asset and working-capital floor — not a forward P/E, not a DCF on Unit II ramp, not an EV/EBITDA multiple borrowed from Akums. The reason is that earnings power for a sub-scale single-site CDMO is inherently unstable across a 5-year window, but the replacement cost of the cleanrooms, FFS lines and the ~₹50 Cr of net working capital is real. The market cap of ₹58 Cr against book equity of ₹55.4 Cr (FY26 BS) and fixed assets net of ₹39.2 Cr plus other assets of ₹52.3 Cr is essentially: "pay 1x book for a real asset base earning a negative spread over the cost of capital today, and decide if the option on Unit II reaching 75% utilisation is worth more than zero."

Sum-of-the-parts is not the right lens here — there are no listed subsidiaries, no investment portfolio, no regulated rate-base, no holding-company stack. The two manufacturing units are reported as a single primary segment per Ind AS 108, and even if they were split, Unit II is too early in its ramp (one full year post-WHO-GMP) to be valued as a separate business. The single asset to underwrite is the same single asset to operate: 357 employees in Solan running two production lines for a fragmented Indian pharma customer base.

6. What I'd Tell a Young Analyst

Watch three numbers in every half-yearly disclosure and stop trying to model the rest: Unit I capacity utilisation, debtor days, and the top-5 customer share of revenue. The first tells you whether Schedule M is delivering displaced orders. The second is the leading indicator of customer financial stress — when brand-owners stretch payables, it shows up at their CDMO before it shows up in their own filings. The third tells you whether the diversification trend (top-5 from 80% to 51% over FY22-FY24) is continuing or reversing.

The market is most likely to mis-price this name in two directions. The overestimate: treating the FY24-FY25 ROCE recovery to ~12% as the new run-rate and applying a peer CDMO multiple (P/E 30-45×); the FY26 collapse to 1.14% ROCE has now disproved that. The underestimate: the Schedule M tail-thinning of unlisted Solan SMEs is a slow, two-to-three-year structural tailwind that the SME-tier market typically does not price until utilisation actually moves; if Onyx prints 70% Unit I utilisation in FY27 with stable debtor days, the setup for a re-rating from P/B 1.05× toward the 1.8-2.2× book band would be on the table.

The thesis changes if (a) a top-3 customer leaves and revenue concentration spikes to 80%+ again; (b) the company files for EU-GMP or USFDA at Unit II — a multi-crore capex that opens a new economic engine; (c) promoter holding at 65.10% changes by more than 3 percentage points in any direction (insider exit signal or strategic stake build); or (d) two consecutive half-years of negative CFO drain working-capital cushion below ₹30 Cr, at which point the asset-floor argument starts breaking. Until one of those happens, this is a book-value name with optionality, not a CDMO compounder.

Long-Term Thesis — Onyx Biotec Limited

1. Long-Term Thesis in One Page

This is not a long-duration compounder unless Onyx evolves from a single-site, paisa-priced sterile-water ampoule shop into a multi-format CDMO with at least one regulated-market accreditation (EU-GMP or USFDA) by FY2030. Without that evolution, the 5-to-10-year case is a tangible-asset floor plus optionality on Unit II utilisation — a ₹58 Cr Solan factory earning a negative spread over its ~12-14% cost of capital, too small to outcompete Innova Captab (₹1,630 Cr revenue, EU-GMP, 30 km away in Baddi) and too large to win on price against the ~1,000 unlisted Solan/Baddi SMEs that Schedule M is supposed to thin. The durable variable is whether the promoter team — running the plant since 2008, holding 65.10% through a 47.5% drawdown — ever signs the multi-crore capex cheque for a regulated-market dossier. The single highest-value multi-year signal is an EU-GMP or USFDA dossier filing announcement at Unit II; every other variable (margins, working capital, ROCE) is downstream of whether the company climbs the regulatory ladder or stays on the conversion-fee escalator.

2. The 5-to-10-Year Underwriting Map

The map below converts each long-term driver into the underwritable form: what has to be true, what we see today, why it could last, and what would break it. The cells are deliberately specific so the next reader of this page in FY2028 can re-grade each row against new evidence.

The single driver that matters most is #4 — regulated-market accreditation. Every other row in this table is either a shared industry tailwind that benefits Innova and Akums equally (rows 1, 2), an operating-leverage call on already-built capacity (row 3), a behavioural-signal driver that is necessary but not sufficient (row 5), or a downstream consequence of the others (rows 6, 7). A 10-year compounder thesis on Onyx cannot survive without a regulated-market dossier — and that dossier is the one row in the table with the lowest confidence today. Read the rest of this page through that lens.

3. Compounding Path

The compounding question for a sub-scale CDMO is simpler than for a branded pharma: it is the product of three numbers — revenue per unit of installed capacity, fixed-cost absorption (utilisation), and capital efficiency on top of the existing asset base. The 5-year history is a stable-growth top line over which margins compounded and then collapsed. The 10-year forward path is one of three scenarios, each tied to a specific capital-allocation choice.

The chart is the compounding story in one frame. Revenue compounded at 11.6% CAGR — respectable but unspectacular for an SME pharma CMO and inadequate to escape the cost-of-capital trap on its own. Operating profit compounded at -12% CAGR over the same five years, because FY26 erased all the gains of FY24 and FY25 in a single year. Cash from operations is the line that matters: five-year cumulative CFO of ₹3.9 Cr against cumulative net income of ₹13.6 Cr means seventy paise of every reported rupee of profit never showed up in the bank account. A business compounds value only if reported earnings convert to spendable cash; Onyx has not yet demonstrated this conversion mechanism over a full cycle.

The ROCE arc tells the rest of the story: a two-year window (FY24, FY25) where Onyx briefly approached the peer-respectable 12-13% level — the IPO window — followed by a 1,170 bps collapse in a single year. Peer median is 15%; Indian SME pharma cost of capital is roughly 12-14%. Onyx has earned a positive spread over its cost of capital in exactly two of the last five years, and one of those was flattered by a 9× one-time spike in other income. The compounding base case is no compounding — the equity tracks book value plus inflation unless one of the scenarios below plays out.

The fair-value column applies a P/B multiple to each scenario's estimated FY2030 book value, calibrated to the operating reality of that scenario (Bear 0.75× book, Base 1.3× book, Bull 2.0× book). On current evidence — margin collapse, CFO negative, FII liquidation, IPO-narrative items going silent — the Bear case is the modal outcome rather than acceleration. The Base case requires only one thing (Unit II ramp without regulatory pivot) and is the consensus bull story; the Bull case requires a capital-allocation decision the promoters have not yet signalled. The 5-to-10-year IRR of holding this equity is governed by which scenario plays out; the probability-weighted IRR on this distribution sits in the mid-single-digit range — below the cost of equity capital, consistent with the stock trading at book.

4. Durability and Moat Tests

A 10-year compounder thesis must survive specific durability tests, not generic "execution risk" hand-waves. The five tests below are competitive, financial, operational and regulatory — each tied to a specific FY27-FY30 evidence threshold.

The pattern across the five tests is consistent: each requires a multi-year accumulation of evidence in a specific direction, and none of the five is currently trending positively. Test 2 (cash conversion) and Test 4 (customer concentration) are the two with the most directly observable evidence over the next 24 months. Test 3 (regulated-market dossier) is the one whose presence or absence by FY2028 most cleanly resolves the bull-vs-bear question — and is the test where management has been most silent.

5. Management and Capital Allocation Over a Cycle

The promoter-family team is the clearest positive in the long-term thesis and the clearest constraint on the most important capital-allocation decision. Sanjay Jain (MD) and Naresh Kumar (WTD) have run this single plant in this single building since 2008. Together they hold 45% of the equity; the broader promoter group holds 65.10% and has not sold a share through a 47.5% drawdown from the IPO price. There are no other listed directorships, no group holding-company stack, no sister concerns visibly being subsidised, no opaque trust structures, no offshore vehicles. By Indian SME standards, the alignment is honest.

What the same evidence cannot tell us is whether this team will make the one capital-allocation decision that matters for the 10-year thesis: filing a regulated-market dossier at Unit II. The historical record on capital allocation since IPO is binary in a different way — the mechanical commitments (debt repayment, Unit II WHO-GMP, promoter holding maintenance, no related-party transactions above 10% of turnover) have all been delivered. The strategic commitments (own-brand LVP launch, export build-out, margin sustainability, profit growth post-IPO) have either failed (exports, FY26 profit) or gone silent (LVP, cartoning line, margin trajectory). The own-brand LVP line — ₹6.07 Cr earmarked at IPO for an Onyx branded large-volume parenteral SKU and the single largest non-debt use of proceeds — does not appear in the FY25 annual report at all. That is the single most informative data point on this management's appetite for moat-building capex: they took the mechanical commitments and let the brand-building one go quiet within six months of listing.

The capital-allocation pattern over the next five years will be the strongest signal on whether this management runs Onyx as a private-asset compounder or as a listed-company growth case. The two are not the same. A private-asset compounder protects what works (Unit I cash flow, promoter dignity, the debt-free balance sheet) and refuses the risky capex. A listed-company growth case takes the multi-crore regulated-market bet at sub-book equity cost, accepts the FCF burn that follows, and earns the right to a 2× book multiple in FY2030. The current evidence is consistent with the first archetype, not the second — which is fine for a 65%-owned family business but inadequate to deliver compounder returns to public shareholders.

6. Failure Modes

These are real thesis-breakers, not generic execution risk. Each is observable in routine filings or competitor disclosures, and each has a specific early-warning signal that lets a future reader update the view before the headline arrives.

The two failure modes with the highest combined severity-and-probability are #1 (customer in-housing) and #3 (sub-book equity raise from working-capital strain). Both are first-order observable in routine filings within the next 18 months. Failure mode #2 (Innova Kathua) is largely out of Onyx's control — it depends on a competitor's capital-allocation choices, not Onyx's own. The lock-in expiry test (#5) is the most binary — it is dated November 2027 and the behavioural signal will be unambiguous when it arrives.

7. What To Watch Over Years, Not Just Quarters

These are the five multi-year milestones that would update — or break — the long-term thesis. Each is a real disclosure, not a guess, and each has a specific validation-and-refutation threshold.

Competition — Onyx Biotec Limited

Onyx holds a commodity position, not a moat. It sells the same FFS sterile-water ampoule and cephalosporin vial that ~1,000 unlisted Solan and Baddi WHO-GMP SMEs sell, and that Innova Captab — a listed peer in the same Himachal Pradesh manufacturing belt — sells at 25× the scale. Schedule M is the one real tailwind, but it raises Onyx's own capex bar even as it thins the unlisted SME tail. The single competitor that matters most is Innova Captab (INNOVACAP): same state, same cephalosporin block, same B2B brand-owner customer base, but at ₹1,630 Cr revenue with 15% ROCE.

The Right Peer Set

The five listed comparators below are not arbitrary. JBCHEPHARM and COHANCE are explicitly named in Onyx's IPO RHP "Basis for Issue Price" chapter as the only two listed peers — that pins the upper valuation envelope. AKUMS is the largest Indian-focused pure-play CDMO (1,400+ clients across 60 dosage forms) and is the structural template Onyx would have to evolve toward. INNOVACAP is the closest like-for-like: same Himachal Pradesh manufacturing belt (Baddi, ~30 km from Solan), same cephalosporin block, same B2B-to-Indian-pharma model, but ten years more mature. SENORES is the closest product-line peer (specialty injectables CMO out of Chhatral, Gujarat) and benchmarks the SME→mainboard IPO runway Onyx aspires to. Concord Biotech was Dan-staged but excluded as a fermentation-API CMO that competes for a different contract pool.

The scale gap is the dominant fact in this table. Onyx prints ₹70 Cr of revenue against an Indian CDMO peer median of ₹2,269 Cr — roughly 1/30th of the peer median, and 1/62nd of Akums. The valuation gap is consistent with the operating-quality gap: P/B 1.05x vs peer median ~4.6x, ROCE 1.1% vs peer median 15.0%. Two of the five peers (JBCHEPHARM, COHANCE) are RHP-cited; two (AKUMS, INNOVACAP) are the strongest economic substitutes on business-model overlap; one (SENORES) is the closest product-line peer for cephalosporin DPI and benchmarks the SME→mainboard re-rating pathway.

Onyx is the bottom-left dot — under 5% OPM and ~1% ROCE — and not because the peer set is forgiving. Every other listed peer in this chart clears 10% OPM and 8% ROCE. The thing this chart hides is the dispersion within the peer set: Senores and JB Chem print 27% OPM on very different stories (specialty injectables + own-brand vs branded formulations + CMO); Innova Captab is the closest read of what a "pure-play CDMO that did the work" looks like when it cleared Onyx's hurdle at scale.

Where The Company Wins

There are exactly three places Onyx still has a defensible position vs the listed peer set — none of them are durable moats, but all three are real enough to factor into the next 24 months.

The honest read of this table is that advantages 3 and 4 are weak — installed-base inertia at the SME end of the market is real but not priced, and a simpler compliance footprint is the consequence of being small, not a competitive choice. Advantage 1 (FFS line unit-cost) is the only genuine micro-edge, and it operates inside a commoditised end-market where ₹0.10 per ampoule moves customer share. Advantage 2 (Schedule M readiness) is the most monetisable, because it converts a regulatory-headwind for unlisted competitors into displaced volume that compliant CDMOs can absorb — but Innova, Akums and others are also compliant, so Onyx will share the displaced pool with the same listed peers it can't outcompete on the rest.

Where Competitors Are Better

The competitive deficit is much larger than the competitive advantage. Four gaps stand out, each tied to a specific listed peer to make the comparison concrete.

Competitive scorecard — 1 (weakest) to 5 (strongest), grouped by dimension then ticker order.

The heatmap reads the same way the table does: Onyx is the weakest column on every single dimension. The closest competitor on absolute scale (SENORES) is at 9× Onyx revenue and 85× Onyx market cap. The closest on business mix (INNOVACAP) is at 23× revenue and 87× market cap and is already in the next state over. There is no dimension on which Onyx is structurally ahead of any listed peer.

Threat Map

The threat catalogue below sorts by what is most likely to take share or compress margin in the next 24 months — not by sensationalism. The single non-listed threat (the unlisted Solan/Baddi SME tail) is rated High because Schedule M is the only event that can either eliminate it or accelerate it; the timing is binary.

The three High-severity threats share one structural property: each one operates inside the customer relationship that Onyx already has, not outside it. A brand-owner that runs its own lines (threat #2) decides every quarter how much volume to outsource. An unlisted Solan competitor (threat #3) sits 30 kilometres away and quotes the same ampoule for ₹0.10 less. Innova Captab (threat #1) is the same brand-owner's preferred vendor for the regulated-market portion of the cephalosporin volume Onyx is trying to win in Unit II. The Medium threats are slower; the Low threats are valuation-shape rather than share-take.

Moat Watchpoints

There are five measurable signals that tell an investor whether Onyx's competitive position is improving or eroding. Each is observable in a routine NSE filing, half-yearly result, or industry data point — none require speculation.

Current Setup & Catalysts — Onyx Biotec Limited

1. Current Setup in One Page

Six days ago (14 May 2026) the board signed off the first full year of audited financials as a listed company; the print invalidated the IPO marketing pitch with revenue ₹69.47 Cr (+10.8%) but a ₹0.21 Cr net loss and operating margin of 4.89% versus 16.76% the year before. The tape had already discounted this — the stock sits at ₹32, almost exactly book value (₹30.6) and 47.5% below the ₹61 IPO price — and the FY26 print delivered no new shock. The live debate is whether H2 FY26's sequential OPM bounce (2.72% → 7.02%) is the trough or a head-fake. The setup is bearish-but-quiet on a microcap that institutions cannot own, with one hard-dated catalyst that matters: the H1 FY27 half-yearly print due November 2026, which tests whether margin recovery is real or whether FY26 is the new normal.

*Recent setup: Bearish / Quiet*

2. What Changed in the Last 3–6 Months

The catalogue below is dated, sourced, and ranked by what still shapes today's setup. Three items are inside the strict 3–6 month window (Feb–May 2026); four 12-month items are retained only because they explain why the market is positioned where it is today.

The narrative arc in three lines. Before September 2025 the market still owned the IPO story: ₹56–60 print, FY25 OPM 16.4%, MarketsMojo upgrade to "very attractive". After H1 FY26 (13 Nov 2025), the market repriced the operating model — the stock halved to ₹30.30 by 20 March 2026 — and after FY26 audited (14 May 2026), it stopped repricing because the print was already in. The unresolved question is whether H2 FY26's 7.02% OPM is the base of a recovery (bull) or a fade back to the H1 trough (bear); only the H1 FY27 print, six months out, settles it.

3. What the Market Is Watching Now

The post-FY26 debate has narrowed to four specific data points. Each will be observable inside the next 6–12 months, three of them in a single disclosure (the H1 FY27 board meeting in November 2026).

Three of the four items above land inside two disclosures: the FY26 Annual Report dispatch (likely September 2026) and the H1 FY27 board meeting (~13 November 2026). There is no third meaningful disclosure between today and those two events. That makes the next six months structurally quiet — the calendar itself, not management silence, is the explanation.

4. Ranked Catalyst Timeline

The ranking below is by decision value to a hedge fund: a catalyst earns rank 1 only if its outcome would force underwriting to change, not because it is closer in time. ONYX has no analyst coverage, no maintained consensus, and no concall, so "consensus" is "not visible" almost everywhere — the disclosure itself becomes the consensus.

5. Impact Matrix — What Actually Resolves the Debate

Of the nine catalysts above, only the four below would force a real underwriting change. Everything else adds information; these update durable thesis variables.

The cleanest read of the matrix: only one item (H1 FY27 results) is both decision-relevant and dated inside six months. One item (FY26 AR dispatch) is dated inside six months but lower impact unless it surfaces a receivables-ageing surprise. The two items that would actually change the 10-year underwriting (regulatory dossier; observable Schedule M displacement) are undated and may not arrive at all. A PM who buys here is paying ₹32 — roughly book value — for one binary print in six months and an option on management ever announcing a regulatory capex cheque.

6. Next 90 Days

The 90-day window (today through ~19 August 2026) is genuinely quiet. The FY26 results print already happened (14-May-2026); the FY26 Annual Report dispatch is on the cusp of the window's far edge (FY25 AR dispatched 2-Sep-2025, so FY26 AR likely just outside 90 days); H1 FY27 results are 180 days out. The realistic 90-day catalogue:

• Quarterly shareholding pattern filing — June 2026 (Q1 FY27). Whether promoter holding stays at 65.10% (expected); whether FII holding floors or breaks below 1% (the FII unwind is largely done but a final touch lower is possible); any DII accumulation. Watch: any promoter holding decline at all (none expected; would be a red flag well ahead of the Nov-2027 lock-in).
• CDSCO Schedule M closure data — anytime through August 2026. No scheduled publication date; could surface in industry reports or trade press. Watch: a number above 200 closures in Solan/Baddi puts magnitude on the tailwind for the first time.
• Any NSE corporate announcement — order win, regulatory inspection, capex commitment. Frequency has been ~1 material disclosure per 4–6 weeks since IPO (mostly contract additions); none would re-rate the equity unless it names an EU-GMP / USFDA filing or a regulated-market customer.
• Innova Captab Q1 FY27 results — early August 2026. The closest like-for-like peer; Kathua block utilisation read-through is the cleanest off-filing signal for Onyx's Unit II competitive position.
• Bulk-deal disclosures — rolling. With FII near zero and the next promoter lock-in 18 months away, any bulk deal of size would be a fresh signal. None expected at current volumes (~₹2.4 lakh ADV).

7. What Would Change the View

The two observable signals that would most change the investment debate over the next six months are (1) the H1 FY27 OPM print and (2) the FY26 receivables-ageing schedule. The first is the single largest near-term test of the Long-Term Thesis margin-recovery driver (#3 Unit II ramp, #6 cash conversion) — a print of OPM ≥10%, debtor days <130, and positive CFO would support the bull's "trough is in" frame and partially close the forensic gap on cash conversion; a print of OPM <7%, debtor days >145, and negative CFO would point the other way, weakening the asset-floor anchor and aligning the setup with the bear's ₹20 adjusted-book target. The second — the receivables ageing schedule that the FY26 annual report should disclose for the first time at full granularity — directly tests the forensic concern that ₹52 Cr of "other current assets" hides impairment; a benign ageing distribution (90% under 90 days) would lift the book-value floor, while >180-day buckets above 10% of total would prompt an impairment scenario consistent with stated book moving from ₹30.6 toward ₹22–26. Beyond those two, the multi-year underwriting question (Long-Term Thesis driver #4) is still about whether management ever announces a regulated-market dossier filing — a signal that has not arrived, is not scheduled, and whose absence through FY2028 would be the strongest single refutation of the compounder case. None of the other items on the timeline — peer signals, bulk deals, governance routine — would change the view on their own, though any could compound a negative signal from the two primary tests.

Bull and Bear

Verdict: Watchlist — the bull has a clean, dated inflection setup; the bear carries the heavier structural case. One half of margin recovery (H2 FY26 OPM 7.02% versus H1 FY26 OPM 2.72%) is not yet enough to offset a five-year cash-conversion failure (cumulative FCF −₹32.35 Cr) layered on top of IPO-era governance scaffolding. At 1.05× book the price already sits near the bear-case anchor — the open question is whether the asset floor is real, or whether the ₹52 Cr "other current assets" line (144-day debtor book) carries a 15–25% real-cash haircut. The H1 FY27 half-yearly print, due September–October 2026, resolves three of the four variables that matter (OPM trajectory, debtor days, CFO sign); until then there is no edge to be long, and governance plus liquidity preclude shorting an NSE SME at ₹58 Cr market cap. Hold the name in the queue; do not commit capital before the print.

Bull Case

Bull target: ₹55 (≈72% upside) over 12–18 months. Method is 1.8× trailing book of ₹30.6 (versus INNOVACAP 4.61×, AKUMS 2.44×), cross-checked at ₹2.73 FY25-normalised EPS × 20× P/E versus peer median 39×. Primary catalyst is the H1 FY27 print (Sep–Oct 2026) with OPM ≥10% AND Unit I utilisation disclosed at 70%+. Disconfirming signal: two consecutive half-years with OPM below 7% AND debtor days above 150 — that combination undermines both the earnings-recovery and the asset-floor arguments.

Bear Case

Bear downside: ₹20 (≈37% downside) over 12–18 months. Method is adjusted book floor: start with FY26 stated book of ₹30.6/share, apply ~15% haircut to the 144-day receivable book and ₹52 Cr "other current assets" (~₹4/share impairment) → adjusted book ≈ ₹26.6, then 0.75× P/B (a defensible discount for a sub-scale single-site SME earning a negative spread over cost of capital) ≈ ₹20. Primary trigger is the H1 FY27 print with OPM below 8% AND debtor days above 130 AND CFO still negative — all three together would refute the bull's central recovery claim. Cover signal: an NSE announcement of EU-GMP or USFDA dossier submission at Unit II, OR two consecutive halves with OPM above 12% AND debtor days below 110 AND positive CFO.

The Real Debate

Verdict

Watchlist. The bear carries more weight today on the durable thesis variables — five years of cumulative FCF at −₹32 Cr against a market cap of ₹58 Cr is not noise, and the IPO-era governance scaffolding (auditor change under casual vacancy, independent directors appointed three months pre-listing, CFO on his own audit committee, 100% pay raises before public shareholders could vote) is not the kind of fact a margin print resolves. The central tension is whether 1.05× book is a floor or a ceiling: the answer depends on the realisable value of the ₹52 Cr "other current assets" line built on 144-day debtor days, and we will not know until H1 FY27 working capital is disclosed. The bull could still be right because the market has already absorbed FII liquidation at this level, promoter holding has held through a 47.5% drawdown, and H2 FY26 OPM of 7.02% is a genuine sequential improvement that — if extended — re-rates a fixed-cost factory; that path is real, just unproven. The near-term evidence marker is the H1 FY27 half-yearly print due September–October 2026, where OPM, debtor days and CFO sign together resolve three of the four variables that matter. Move to Lean Long if the H1 FY27 print shows OPM ≥10% AND debtor days ≤130 AND positive CFO; move to Avoid if any two of OPM ≤7%, debtor days ≥150, or another negative CFO appear together — anything in between keeps the name on Watchlist with no committed capital.

Moat — What Protects This Business, If Anything

The judgement on Onyx is No moat. The company is a price-taker in a commoditised conversion layer of Indian pharma — its FY26 ROCE of 1.1% against a peer median of ~15% is the summary statistic that matters. There is no switching cost a multi-thousand-crore brand-owner cannot pay in 60-90 days, no regulated-market accreditation locking in pricing, no scale economy, no specialty IP. The one structural force on Onyx's side is Schedule M — the December 2025 regulatory tightening that should thin the ~1,000 unlisted Solan/Baddi WHO-GMP SME competitors — but the tailwind is shared with every listed peer in the segment. The stock at ₹32 (1.05× book) prices this consistently: book-value plus a small option on Unit-II utilisation, not a moat compounder.

1. Moat in One Page

The reader should walk away with three sentences. First, Onyx sells a commodity ampoule and a generic cephalosporin DPI vial — both are paisa-priced products where a ₹0.10 swing per ampoule is two-thirds of full-year operating profit. Second, the customers that pay Onyx (Sun Pharma, Mankind, Aristo, Macleods, Hetero, Reliance Life Sciences) are 100× to 1,000× larger and also run their own injectable lines — they outsource only their peak load. Third, the listed competitors that matter most (Innova Captab, Akums) are at 23× to 62× Onyx's revenue scale in the same Himachal Pradesh manufacturing belt, with the EU-GMP and USFDA dossiers Onyx does not have. Confidence in the conclusion is high; confidence that Schedule M will eventually move the needle is medium; confidence that any company-specific moat will emerge in the next 24 months is low.

2. Sources of Advantage

The table below walks through every category of moat that an investor might hypothesise for a sub-scale Indian sterile CDMO. Proof quality is graded High when the advantage shows up in returns, margins, retention or pricing data; Medium when the advantage is plausible but unverified; Low when the advantage is asserted but contradicted by the data; Not proven when there is no evidence either way.

The honest read of this table is that no candidate source clears a High bar. The single Medium is embedded-customer-workflow, and even that is capped at the SKU level — a customer that wants to leave can do so over 12-24 months without paying a destructive switching cost. Every other category is either Low (evidence contradicts the moat claim) or Not proven (no evidence either way). This is what "No moat" looks like in a table.

3. Evidence the Moat Works — or Doesn't

A moat must show up in business outcomes: returns, margins, retention, pricing or share. The ledger below tabulates the seven most decisive pieces of evidence visible in Onyx's filings, financials and peer data. Six refute the moat hypothesis; one is ambiguous; none support it.

The pattern is unanimous. The strongest piece of "moat-like" evidence is item 2 — long-tenured top-customer relationships — but that very evidence is also consistent with simply being a competent, reliable, cheap second-vendor that customers retain because there is no upside to firing them. A genuine moat would show up in items 1, 3, 4 and 5: superior ROCE, faster collection, defended margin, premium pricing. None of those signals are present.

4. Where the Moat Is Weak or Unproven

This section is tough on the company by design. The bull case on Onyx ultimately rests on (a) Unit-II ramping to 70%+ utilisation, (b) Schedule M displacing unlisted SME volume to compliant CDMOs, and (c) eventual regulated-market dossier filings. Each of these is either an execution call or a shared-industry tailwind — none is a company-specific moat.

5. Moat vs Competitors

The peer set is curated for business-model overlap rather than market-cap match. Innova Captab is the closest like-for-like (same Himachal Pradesh manufacturing belt, same cephalosporin block, same B2B-to-Indian-pharma model, 23× the scale). Akums is the structural template a scale-up CDMO would have to evolve toward. JBCHEPHARM and COHANCE are explicitly RHP-cited as listed peers. Senores benchmarks the SME→mainboard re-rating pathway.

The picture is unambiguous. Every listed peer clears 10% OPM and 8% ROCE. Onyx is the bottom-left dot — not because the peer set was filtered to be flattering, but because a moat shows up in returns and Onyx has none to show. The closest like-for-like (Innova) operates at 15% ROCE on 23× the revenue scale in the same manufacturing belt — that is the structural ladder Onyx would have to climb, not a peer set with built-in selection bias.

6. Durability Under Stress

A moat must survive stress to matter. The table below stress-tests Onyx's competitive position against six scenarios — recession, customer churn, input-cost shock, regulated-market entry by peers, technology shift, and Schedule M shortfall. The pattern is consistent: Onyx is un-stressed only in the absence of stress.

The conclusion is consistent across the stress cases: none of them produce a "moat holds" outcome. The closest the company has to a defensive moat is geographic + WHO-GMP compliance — both of which protect Onyx from the unlisted SME tail but not from any listed peer. Durability is graded 18 / 100 — the floor is the tangible-asset value of the Solan plant, not a competitive position.

7. Where Onyx Biotec Limited Fits

The moat — to the extent any can be argued — lives in Unit I (sterile water for injections, FFS ampoule line, 638,889 units/day capacity) at the SWFI commodity end of the market. The in-house multi-column distillation feeding the FFS line gives Onyx the lowest unit cost among the unlisted Solan SME tail, and the 14-year top-customer tenure suggests it has graduated above the casual-spot-PO segment for at least its top names. This is not a moat in the academic sense; it is cluster-cost-leadership at the unlisted-SME end, and it protects Onyx from the bottom 1,000 competitors while leaving it exposed to the top 5 listed peers.

Unit II (cephalosporin DPI 40,000 vials/day + dry syrups 26,667 units/day) is the part of the business where any future moat would have to be built — but it is currently a ramp-stage commodity line operating at sub-50% utilisation against an Innova Captab block at 23× the scale in the same state. The only way Unit II earns a defensible position is regulated-market (EU-GMP / USFDA) accreditation, which requires multi-crore capex Onyx has not committed to. Until that capex is announced, Unit II is an operating-leverage call, not a moat.

The thing newcomers most often miss is that Onyx is not a uniform business with a uniform competitive position. Unit I sits in a commoditised price-taker pool where its in-house WFI integration is a real but small edge against the bottom thousand competitors. Unit II is a ramp-stage line with no edge at all against listed peers. Treating the company as "one CDMO" instead of "one cost-leader SWFI plant plus one unproven DPI ramp" misreads the operating picture.

8. What to Watch

Five signals tell an investor whether the (currently absent) moat is starting to build or whether the price-taker position is deepening. Each is observable in routine NSE half-yearly filings, CDSCO inspection logs or competitor disclosures — none require speculation.

The first moat signal to watch is Unit I capacity utilisation in the next half-yearly disclosure. A sustained move above 70% is the one data point that would turn "shared Schedule M tailwind" into "Onyx-specific volume win" — without it, no other moat-building activity in this business has a runway.

Financial Shenanigans — Onyx Biotec Limited (ONYX)

The forensic verdict on Onyx Biotec is Elevated-to-High risk (62 / 100) — not on evidence of misconduct, but because the IPO-year income statement does not reconcile to the cash-flow statement and the governance scaffolding around the November 2024 listing is thin. Over five years the company reported ₹13.56 crore of cumulative net income while generating only ₹3.90 crore of operating cash and burning ₹32.35 crore of free cash flow. Other income jumped 9× in the listing year and then normalised; debtor days tripled from 47 to 144 between FY2023 and FY2026; operating margin fell from 16.76% to 4.89% in the first full year as a public company. None of this is a fraud accusation — the statutory auditor's report is unqualified — but the pattern of "paper profits that never become cash" is the cardinal earnings-quality flag in the forensic playbook, and it is unusually loud here.

1. The Forensic Verdict

The two biggest concerns are (a) the structural disconnect between reported profit and operating cash flow, and (b) the IPO-year other-income spike that flattered headline earnings just before listing. The cleanest offsetting evidence is the unqualified statutory audit report, the unchanged 65.10% promoter holding (no insider exit), and the disclosed use of IPO proceeds with no reported deviation. The single data point that would most change the grade: the FY2026 audited financials confirming whether debtor days continue to expand past 144 or whether collections normalise.

Shenanigans Scorecard

2. Breeding Ground

The setup around the November 2024 IPO is the structural reason every downstream forensic flag warrants a higher confidence level. The company listed on NSE Emerge — the SME segment — which carries explicit exemptions from large parts of SEBI LODR, half-yearly (rather than quarterly) reporting, and the absence of mandatory Ind-AS adoption. None of these are wrongdoing; they simply lower the disclosure surface and make scrutiny harder.

3. Earnings Quality

The income statement looks healthy in the IPO year and broken in the year after — and the gap between the two is mostly other income, depreciation phasing, and a one-time post-listing collapse in operating leverage. Operating margin rose from 11.4% in FY23 to 16.76% in FY25, then collapsed to 4.89% in FY26. The expansion was real but partly cosmetic; the contraction is a warning that the IPO-year P&L was the high-water mark, not the new run rate.

Other-income spike inflated the IPO year

Other income in FY2025 was ₹1.17 crore — nine times the FY2024 level of ₹0.13 crore, and at par with the next three FY24/23/22 readings combined. It contributed 11.3% of operating profit and roughly 16% of pre-tax profit in the listing year. In FY26 it normalised to ₹0.44 crore. The annual report does not break the composition; for a contract manufacturer without investments, "other income" typically comprises interest on bank deposits, foreign exchange gains, scrap sales, and rate-difference recoveries — and the spike coincides precisely with IPO proceeds being parked in deposits before deployment.

Stripping the one-time portion of FY25 other income (using the FY24 baseline of ₹0.13 crore) trims roughly ₹1.04 crore from pre-tax profit, taking PBT from ₹6.48 crore to ₹5.44 crore — a 16% reduction in headline profitability. That alone would have made the post-tax growth narrative ("PAT up 36.32%") look closer to flat versus FY24.

Receivables and inventory grew far faster than revenue

The single largest forensic concern is the divergence between revenue growth and the growth of receivables, inventory and other current assets. Across FY24-FY25 the asset side expanded by 89% and 64% while revenue grew 36% and 15%. The IPO year added ₹19.7 crore to the "other assets" line — more than four times the year's reported net income.

The MDA itself flags the deterioration: debtors-turnover dropped from 5.26 times (FY24) to 3.48 times (FY25). Translated into days, that is debtor days expanding from 47 to 119, and 144 by FY26 per the ratios file. For a domestic contract manufacturer selling primarily to large Indian pharma, 90 to 120 days is plausible — but a tripling within three years, peaking around the listing, is the textbook receivables-quality flag from the shenanigans playbook.

4. Cash-Flow Quality

The most decision-relevant finding in this entire memo is the gap between cumulative net income and cumulative operating cash flow over the past five fiscal years. The company has reported ₹13.56 crore of net income; it has generated ₹3.90 crore of operating cash. Free cash flow has been negative every year except FY25, totalling ₹-32.35 crore. This is the inverse of the classic cash-flow shenanigan: rather than CFO being boosted to flatter the picture, CFO is being held down by working-capital expansion that the income statement does not show. Either the working-capital build is a structural feature of scaling a contract manufacturer with concentrated big-pharma customers, or revenue is being recognised in periods where the underlying cash never arrives.

The decomposition is straightforward: the ₹9.66 crore gap between cumulative net income and cumulative CFO over five years matches almost exactly the ₹36.7 crore growth in receivables/inventory/other current assets net of payable expansion. There is no evidence of factoring, securitisation, supplier-finance or boomerang transactions in the cash-flow statement; debt was paid down with IPO proceeds (₹30.78 cr → ₹12.46 cr) and re-built modestly in FY26 (₹15.17 cr). So the structural cash-flow weakness reflects the working-capital story, not financing engineering.

5. Metric Hygiene

The IPO-year annual report leans heavily on three metrics: revenue from operations (₹61.95 cr, +15.3% YoY), PAT (₹4.95 cr, +36.3% YoY) and ROCE (11.88%, up from 11.22%). Each is correctly reported in absolute terms but each becomes less impressive once normalised for the IPO event or for the trajectory it preceded.

The peer-relative test is straightforward. Across the FY26 reporting window, listed pharma CDMO peers reported operating margins of 12% (Akums), 15% (Innova Captab), 19% (Cohance) and 27% (JB Chemicals, Senores). Onyx's FY26 operating margin of 4.89% sits below every peer in the panel. The FY25 reading of 16.76% was in line with the lower end of the cohort; FY26 fell off it.

6. What to Underwrite Next

Five items would shift this forensic grade in either direction. Track them.

In one sentence: until ₹52 crore of "other current assets" turns into cash, the income statement should be read as indicative — not authoritative — of economic profit at Onyx Biotec.

The People Running This Company

Governance grade: C. Onyx Biotec is a tightly-held Jain family pharma SME — promoter control is 65.1%, zero pledged — but the post-IPO board carries the hallmarks of cosmetic compliance: three independent directors all appointed in the four months before listing, the CFO/CEO sits on the audit committee, and the managing director doubled his own (and his three colleagues') pay by 100% in the IPO year. Skin in the game is real; check-and-balance is light.

1. The People Running This Company

The executive bench is four men paid identically, with two long-tenured founder-promoters at the centre and a recently-added CEO/CFO who is also a promoter. Capability is concentrated in two people who have run this plant since 2008; succession beyond them looks thin.

Why this matters. Sanjay Jain and Naresh Kumar built the business; they own 45% of the company between them and have nowhere else to be. But the bench below them is the worry: Harsh Mahajan wears three hats (CEO, CFO, WTD) at 38, and Lakshya Jain — the only person under 60 with operating depth — is the MD's family member with eight years total experience and no personal stake yet. The "succession plan" is biological.

2. What They Get Paid

Pay is small in absolute terms — ₹1.2 crore in aggregate across four executive directors — but every promoter director got a 100% raise in the IPO year while the median employee got 23%. That ratio (executive 100% / staff 23%) is the disclosure to read twice.

Is it earned? On absolute size: yes. ₹30 lakh/year ($35k at FY25 close) for an MD running a ₹62 crore-revenue pharma plant is below India market for the role. On timing: less defensible. The 100% hike was approved in the same window the company was preparing the RHP — the AR notes new appointments dated May 2024 and increases effective FY25. Pay doubled before public shareholders could vote on it. And the company posted ROCE of just 1.14% and ROE of -0.38% in the reported year (per Screener), so the doubling preceded any operating evidence to justify it.

3. Are They Aligned?

Ownership alignment is genuinely strong. Three promoter individuals hold the entire 65.10% block and not a single share is pledged. There has been zero promoter selling in the four quarters since listing. The smart money flowed out — FIIs unwound from 8.72% to 1.07% — but that was IPO allotment churn, not promoter behavior.

Related-party behavior. Per the RHP, promoter family members have historically drawn salaries from the company outside of director pay — Meenu Jain (Sanjay's spouse), Anita Mahajan (Harsh's spouse), and Mehak Sood Walia at ₹10–30 lakh/year ranges. In FY24 (pre-IPO), the company also carried ~₹1.5 crore of unsecured loans from Sanjay Jain, Naresh Kumar and Harsh Mahajan personally. None of this is unusual for a closely-held Indian SME, and the FY25 AR confirms no related-party transaction exceeded 10% of turnover. But the boundary between family and company finances is porous — the AR's own related-party note lists "gifts" passed between Anita Mahajan, Meenu Jain, Sanjay Jain and Naresh Kumar of ~₹10 lakh apiece, and salary-payable balances to nine family members at FY24 year-end.

Capital allocation behavior. IPO raised ₹29.34 cr, of which ₹12 cr (41%) went to repaying promoter and bank loans rather than growth. No dividend yet (company says "to augment working capital"). Authorised capital was hiked from ₹14 cr to ₹20 cr in FY25, leaving headroom for further dilution. No buyback. No ESOP plan disclosed.

Skin-in-the-game score: 7/10. Owners genuinely own the business (top three promoters hold 65%, zero pledge, locked-in cohort still 31% of equity until 2027). They bleed when the stock bleeds — and the stock is down 47.5% from its IPO issue price of ₹61. Three points withheld for: the IPO-year pay doubling, the related-party salary roster for family members, and the use of public capital partly to retire promoter loans.

4. Board Quality

Eight directors. Three independent. The five non-independent seats are all held by promoters (four executive + Parmjeet Kaur as the non-executive woman director, who is also a promoter). Onyx is on the NSE EMERGE SME platform, which exempts it from most of SEBI LODR's tougher board-independence rules — and the board structure reflects that exemption rather than rising above it.

The structural problems.

Harsh Mahajan is CFO, CEO, a Whole-Time Director, and a member of the Audit Committee. That is the single biggest specific governance defect in the filing. The Audit Committee's job is to scrutinise the CFO's numbers. Having the CFO sit on the committee that audits him collapses the check.

All three independent directors joined in July 2024 — four months before listing. They have no operating history with the company. Their independence is "formal" (meets Section 149(6) criteria, signed declarations) but not "real" (no track record of pushing back).

No independent woman director. Parmjeet Kaur is the woman director on the board, but she is also a promoter. The SME exemption permits this, but it means the board has no independent woman's voice and the gender diversity disclosure is technically met without substantively meeting it.

Concentrated chair load. Nitesh Garg chairs both the NRC and the Stakeholders Relationship Committee. Vineet Singh chairs the Audit Committee. Two of the three IDs are doing all the committee work — fine for a small board, but a lot of weight on people in their first listed-board role.

Board Skills Matrix — 0=none, 1=basic, 2=working, 3=deep.

Missing expertise. No board member has a public-markets or investor-relations track record. No board member has pharma-regulatory deep expertise (USFDA, EU-GMP) despite the company's stated overseas-export ambition. No audit-firm partner, no PSU/banking professional, no listed-board veteran among the IDs.

What works. Zero litigation — against the company, the directors, or the promoters. Statutory auditor (R C A and Co LLP) issued an unqualified report. Whistleblower policy in place. Independent directors held one meeting without management on 29-03-2025 (the minimum required). All 10 board meetings during FY25 had full attendance from the two MDs being re-appointed. The mechanical compliance is clean.

5. The Verdict

Governance grade: C.

What works (strongest positives):

Owners eat their own cooking. 65.10% promoter holding, zero pledged, zero promoter selling through a 47% price drawdown. Three named promoter individuals hold the entire promoter block — no opaque trust structures, no offshore vehicles.

Disclosure hygiene is clean. No qualified audit opinion, no SEBI/regulatory actions, no litigation against directors or promoters, no material RPT above the 10%-of-turnover threshold. The mechanical filings are in order.

Operators, not raiders. Sanjay Jain and Naresh Kumar have run this single business in this single building since 2008. There are no other listed-company directorships, no group holdings, no sister concerns visibly being subsidised.

Real concerns:

CFO on the Audit Committee. Harsh Mahajan is CFO, CEO, a Whole-Time Director, and sits on the committee that should audit him. Fixable with one resignation, but currently a structural failure.

100% pay hike in the IPO year. All four executive directors saw managerial remuneration double in the year the company listed. Median employees got 23%. No performance-linked component is disclosed.

Cosmetic independence. All three independent directors were appointed in July 2024, just before listing. None has a public-markets track record. Their committee work is the only governance check on a board that is 5/8 promoter.

Family salary roster. Per the RHP, four named promoter spouses/relatives drew salaries from the company in the years leading to IPO. The FY25 AR says no RPT exceeded 10% of turnover, but the boundary remains porous.

What would change the grade:

Upgrade to B if: Harsh Mahajan steps off the Audit Committee, an independent pharma-regulatory voice joins the board, and FY26 pay decisions show restraint after the IPO-year jump.

Downgrade to D if: promoter pledging appears, a material related-party transaction is approved without independent-director scrutiny, the second-anniversary lock-in (Nov-2027) is followed by promoter selling into a weak stock, or the IPO-proceeds utilisation deviates from the RHP plan.

The watch item. Onyx sits at the intersection of two real risks — operating returns have collapsed (ROCE 1.14%, ROE negative in TTM per Screener) while management just doubled its pay. Outside shareholders are paying for an IPO-year pay reset now disconnected from performance. That is what to track in FY26 AR disclosures.

The Story

Onyx is a 20-year-old contract manufacturer that became a public company 18 months ago, in November 2024. Its full disclosure footprint is one annual report, one prospectus, two presentations, and 18 months of price action. The story is short and has already turned: an IPO sold on capacity expansion and margin expansion was followed, two reporting periods later, by margin collapse and a full-year net loss. The promoter team has delivered the mechanical promises (debt repayment, Unit-II ramp) and has been silent on the larger ones (margin trajectory, international expansion, the Large Volume Parenterals brand). Credibility is not broken — no scandals, no auditor flags, no governance accidents — but it is leaking.

1. The Narrative Arc

The current strategic chapter starts in 2023, when Unit-II came online and changed the business from a single-product SWFI supplier into a three-format contract manufacturer (sterile water, dry powder injections, dry syrups). The MD, Sanjay Jain, has run operations since 2008 but was only formally appointed Managing Director on July 23, 2024 — four months before the IPO. So the present management is also the founding management; this is not a turnaround team inheriting someone else's company.

Why this matters

• The IPO valuation rested on a single year of accelerating profitability (FY24 → FY25) on capacity that had just been installed. There is no long-arc track record to fall back on.
• FY2026 — the first full fiscal year as a listed company — was a net loss. That is not the inflection point management's IPO marketing pointed at.

2. What Management Emphasized — and Then Stopped Emphasizing

The IPO prospectus (Nov 2024) and the FY25 Annual Report (May 2025) cover almost the same window but their relative emphasis on key themes shifts meaningfully. The heatmap below codes how much space each theme received (0 = absent, 5 = repeated headline).

Topic emphasis: IPO marketing vs first AR as a listed company.

Three patterns stand out:

• The own-brand LVP line dropped out of the narrative. The IPO earmarked ₹6.07 crore — the single largest non-debt use of proceeds — to upgrade Unit-I to produce Large Volume Parenterals under the Onyx brand. The FY25 AR does not mention LVPs, an LVP launch timeline, or a brand-building plan. The capex object has gone quiet.
• Exports collapsed in the narrative because they had no underlying activity. The RHP repeatedly described "India and overseas" markets. The FY25 AR's Annexure 2 reports Foreign Exchange earnings: NIL and Foreign Exchange outgo: NIL for both FY24 and FY25. The export pillar exists in the prospectus and not in the financials.
• India-macro padding expanded as company-specific content thinned. The FY25 MD&A spends roughly twice as much space on IMF/World Bank GDP commentary, US fiscal policy and India pharma sector statistics as it does on Onyx itself. That is a tell.

3. Risk Evolution

Onyx's NSE SME annual report is not required to carry a SEC-style Risk Factors section. The IPO RHP filed 33 internal risk factors (Nov 2024); the FY25 AR's MD&A "Risks and Concerns" is a one-paragraph cautionary statement. Below: how the substance of those risks has actually played through the first 18 months of public-company life.

Risk evolution — disclosed at IPO vs realized over FY26.

The risks that have actually moved are profitability and working capital, neither of which the prospectus flagged as a top-tier concern.

Debtor days have nearly tripled (47 → 144) in three years; the cash conversion cycle more than tripled. The IPO RHP disclosed the concept of payment-delay risk but the disclosed FY22–H1-FY25 numbers did not look stressed. They look stressed now.

4. How They Handled Bad News

Onyx's first piece of bad news as a listed company arrived in the H1 FY26 disclosure (filed early November 2025). Operating margin had collapsed from 18.94% in H1 FY25 to 2.72% in H1 FY26 — a drop of more than 16 percentage points in a single half. The half closed in a net loss.

Three behaviors deserve attention:

• Silence. NSE SME companies do not host quarterly earnings calls, but they are allowed to. Onyx did not. There is no investor communication explaining the H1 FY26 collapse — no press release, no presentation, no statement on the company site. The only public commentary is third-party (MarketsMojo coverage on Sept 19 and Sept 29, 2025) noting "the lack of available positive or negative factors further complicates the outlook, as there are no specific catalysts mentioned."
• The dividend signal. The FY25 AR justified the dividend skip with: "To strengthen the financial position of the Company and to augment working capital, your directors do not recommend any dividend for the FY 2025." In hindsight that is consistent with a board that already knew working capital was tight — debtor days went from 119 (FY25) to 144 (FY26).
• A 100% rise in managerial remuneration, in the year before the loss. The FY25 AR discloses that managerial remuneration rose 100% during FY25 vs 23% for the median employee. That increase was approved before management had visibility into the FY26 margin collapse — but the optics of a doubled MD payslip immediately before a swing-to-loss year are poor, and management has not addressed them.

5. Guidance Track Record

Onyx has made very few formal guidance statements. The promises that mattered to valuation were embedded in the IPO Objects of the Issue and the strengths section of the RHP. Here is the scorecard for the ones a buyer would have cared about.

Why 4/10. The mechanical, calendar-driven promises (raise the IPO, repay the debt, hold the promoter stake, keep WHO-GMP, stay clean on related parties) have all been delivered. The promises that required operating execution under public-company scrutiny — own-brand LVP launch, export build-out, margin sustainability, profit growth — have either failed (exports, FY26 profit) or gone silent (LVP, cartoning, margin trajectory). The score is not lower because there is no evidence of fraud, no auditor qualification, no regulatory penalty, and no governance accident. The score is not higher because the company has not communicated through the first real test, and because the IPO marketing materially understated working-capital risk that has now crystallized.

6. What the Story Is Now

The current story is much simpler than the IPO pitch, and meaningfully less attractive.

What has been de-risked:

• Capital structure is no longer the binding constraint. Net debt is small (~₹15 cr at FY26-end on equity of ~₹55 cr). The promoter group still owns 65%, with credible alignment.
• The regulatory footprint is clean. WHO-GMP for both units, no auditor qualifications, no SEBI/SEBI-LODR penalties, no IBC proceedings, no material litigation.
• Capacity exists. Unit-II is built. The bottleneck is no longer manufacturing capacity.

What still looks stretched:

• Operating margin. FY26 op margin (4.89%) is the worst of the five reported years. The 16-percentage-point collapse from H1 FY25 to H1 FY26 has not been explained.
• Working capital. Debtor days of 144 and a cash conversion cycle near 120 days for a contract manufacturer with ₹69 cr of revenue is not viable. Either the customer mix is shifting toward weaker payers, or order book quality is dropping. Neither has been disclosed.
• The own-brand LVP line. The single biggest IPO-narrative item beyond debt repayment has gone silent. If it launches, the story is alive; if it never appears, the IPO documentation was aspirational.
• The export pillar. Currently zero. The prospectus treated "overseas" as a forward growth lever; the AR confirms it has produced no foreign exchange.

What the reader should believe versus discount:

• Believe the disclosed financial trajectory through FY26 — the auditors haven't qualified anything and the half-yearly breaks are internally consistent.
• Believe that the promoter family is committed (65% holding, personal guarantees still in place against bank facilities).
• Discount the "international" and "own-brand LVP" portions of the IPO pitch until the company publishes concrete evidence (first export invoice, first LVP order, first commissioning announcement).
• Discount any inference that management will proactively explain operating misses. The H1 FY26 collapse was met with silence; treat that as the base case for future bad news.

Financials — What the Numbers Say

Onyx Biotec is a ₹58 crore contract manufacturer of sterile water for injections, dry powder injections and dry syrups, run by promoters who still own 65% post-IPO. Five years of steady top-line growth (₹44.9 Cr → ₹69.5 Cr) and an FY2025 margin peak of 16.8% masked a fragile cash engine, and FY2026 broke the model — operating margin to 4.9%, ₹0.21 Cr net loss, cash from operations negative, debtor days 144, ROCE from 12.2% to 1.1%. The stock trades at one times book (₹32 vs ₹30.6 BV) because the market has marked the business down to its hard-asset value while it waits for margin recovery. The number that matters now is FY2027 H1 operating margin: a print below 10% would weaken the equity story.

Quality Score, Fair Value, Predictability, Altman Z, and Piotroski F are unavailable — the standard scoring providers do not cover NSE SME microcaps. Where a third-party score would normally appear, this page uses primary financial data and peer comparisons instead.

How to read this page

Onyx is an NSE SME microcap and reports half-yearly (H1 / H2), not quarterly. Currency is Indian Rupee (₹). One crore (Cr) is 10 million rupees, so revenue of ₹69.47 Cr is roughly ₹695 million. All figures shown here are standalone — the company is too small to file consolidated accounts. Where a term is technical, it is defined on first use, then used normally.

---

1. Revenue, Margins, and Earnings Power

Revenue has compounded at roughly 11.6% per year over five fiscals — respectable but unspectacular for an SME pharma CMO. The shape that matters is not the growth line, it is the divergence between revenue (rising) and operating profit (collapsing in FY2026).

Reading the chart. Revenue rose every year except FY2023 (the COVID-tail correction), accelerated through the IPO year, and posted its highest absolute level ever in FY2026 — yet net income went negative for the first time. That is the textbook signature of margin compression overwhelming volume growth.

Margin profile

Operating margin is operating profit divided by revenue; for a contract manufacturer like Onyx, it captures how much of each rupee of customer billing survives after raw materials, labour, power, and factory overheads. The five-year arc shows the FY2026 break clearly.

Margins expanded steadily from FY2023 to FY2025 as Unit II (dry powder injections, cephalosporins) ramped and the WHO-GMP certification (May 2024) opened higher-value contracts. The FY2026 drop is not a small slip — it is a 1,187 basis-point swing in a single year (16.8% → 4.9%) with no offsetting volume tailwind to explain it. The company's MD&A points to raw-material inflation, customer pricing pressure, and under-absorbed fixed costs as production was reshuffled around the new high-speed carton line.

The H1 / H2 cadence — where the break actually shows

Annual numbers smooth the inflection. The half-yearly series shows that the operating-margin collapse landed in H1 FY2026, when OPM crashed from 14.6% to 2.7%, and only partially recovered in H2.

H2 FY2026 came in at 7.0% — better than H1 but still less than half the company's FY2025 average. The trajectory is bottoming, not recovering — the read is "stabilising at a much lower level," not "snapping back."

---

2. Cash Flow and Earnings Quality

Free cash flow is the cash a business generates after paying for operations and capital expenditure. It is the only profit metric you can actually spend. For Onyx, the gap between reported net income and FCF has been the most important — and most under-discussed — feature of the financials.

Cash conversion has been weak for five straight years. Operating cash flow has trailed net income in every period — by a wide margin. In FY2025, the company reported ₹4.95 Cr of net income but only ₹1.42 Cr of CFO — a 29% cash-conversion rate. That means roughly seventy paise of every reported rupee of profit never showed up in the bank account. In FY2026 the gap goes the other way (loss above CFO loss), but the direction is the same: CFO is negative and FCF is deeply negative.

Note: FY2026's "conversion" ratio (7.1x) is mechanical — CFO is negative on a small net loss, so the ratio is meaningless. The honest read is that 2022–2025 cash conversion averaged roughly 21% — earnings were largely paper.

Where the cash leaked

The cash story is dominated by working capital absorption and a fixed-asset build cycle that ran from FY2023 to FY2024. The 2022–2026 period contains roughly ₹19 Cr of cumulative net income but ₹3.9 Cr of cumulative CFO and −₹32.4 Cr of cumulative FCF.

The FY2023 spike is the Unit II commissioning. The FY2026 capex bump (₹5.0 Cr) reflects the high-speed carton packaging line being built with IPO proceeds — that is the planned, disclosed use of funds, not a surprise. The issue is that the new capacity is not yet earning its keep: it is consuming working capital while the customer book is being seasoned.

Working-capital decomposition

Working capital tells the cash story in one frame.

Receivables tell the loudest story. Debtor days — how long customers take to pay — have more than doubled from 47 (FY2023) to 144 (FY2026). That means the company is effectively financing roughly five months of revenue for its customers. The customers (Mankind, Sun Pharma, Dr Reddy's, Aristo, Macleods) are large, creditworthy buyers, but they are using Onyx as a cheap working-capital source. The cash conversion cycle — the round-trip from cash spent on inventory to cash collected from customers — has climbed from 37 days to 119 days. That is the single biggest reason CFO never matches reported earnings.

---

3. Balance Sheet and Financial Resilience

The IPO in November 2024 reset the balance sheet. Equity nearly tripled, and gross debt fell from ₹30.8 Cr to ₹12.5 Cr. The structure today is conservative — the question is whether it provides flexibility or just delays the inevitable.

Pre-IPO (FY2022–FY2024): debt-funded capex build, debt-to-equity ratio peaked at 1.6x in FY2023. Post-IPO (FY2025–FY2026): debt-to-equity at 0.22x — well below the Indian pharma SME median.

Coverage and resilience

Interest coverage (operating profit ÷ interest expense) has fallen from 8.9x to 2.8x. At the current run-rate of half-year operating profit (₹2.4 Cr in H2 FY26 against ₹0.66 Cr of half-year interest expense), the cushion is much thinner than the annual ratio suggests. The quick ratio (current assets less inventory, divided by current liabilities) at 2.1x looks comfortable — but that liquidity is mostly stuck in receivables, not cash. The IPO inflated current-asset balances faster than current liabilities, but the company still ran negative CFO in FY2026, which means the apparent liquidity is not converting.

The verdict on the balance sheet is "adequate, not bullet-proof." There is no immediate solvency risk — promoters can re-lever a clean balance sheet, the bank lines are intact, and the IPO cash has not all been spent. But the company is one year of FY2026-style operations away from needing to choose between (a) raising more debt, (b) tapping promoters, or (c) issuing equity again. Of those three, equity at ₹32 (1.05x book) is dilutive precisely when the business is least able to defend it.

---

4. Returns, Reinvestment, and Capital Allocation

Return on capital employed (ROCE) is operating profit divided by the capital used to earn it (equity plus debt). It tells you whether the business compounds value or just grows the asset base.

FY2024–FY2025 ROCE of 12–13% was the brightest moment in Onyx's financial life — close to (but below) JBCHEPHARM's 25.8%, INNOVACAP's 15.0%, SENORES' 15.1%. The FY2026 collapse to 1.1% is not just a margin event; capital employed expanded (more capex, more receivables, more inventory) while operating profit shrank — both ends of the ratio moved the wrong way.

How management has used capital since the IPO

The IPO raised roughly ₹29 Cr of net proceeds (₹58 Cr issue minus expenses, minus dilution math); the use of those funds breaks down as: roughly two-thirds went into deleveraging, the rest into capex and working capital. No dividend, no buyback, no acquisition — pure operating use. That is the right call for a small CMO trying to compound, but it depends on the operating engine working, and FY2026 has called that into question.

Per-share economics

EPS halved in FY2024 as the share count tripled (₹13.3 lakh shares became ₹181.3 lakh shares — the bonus issue ahead of the IPO and then the IPO itself). Book value per share, the more meaningful denominator post-IPO, has held flat at ~₹30.6, which is exactly the level the stock trades at today. The market is paying ₹32 for ₹30.6 of book — almost no premium for the going-concern.

---

5. Segment and Unit Economics

Onyx reports a single operating segment (pharmaceutical contract manufacturing) under Ind AS 108, so segment financials do not exist. What does exist is product-line and customer-concentration disclosure in the IPO RHP, which has been the most useful pseudo-segment view.

Sterile water is the legacy cash cow (capacity built over 15 years, six FFS machines, high-volume low-margin); dry powder injections and dry syrups (Unit II) are the new growth engines — higher margin per unit but smaller volumes, and the segment that needed WHO-GMP certification to access export markets.

Customer concentration

This is the segment view that actually matters for risk.

Concentration has moderated — top-5 share dropped 29 percentage points in two years — but top-10 still represents 71% of revenue. The customer list (Mankind, Sun, Dr Reddy's, Aristo, Macleods, Hetero, FDC, Reliance Life Sciences) is high quality, but those buyers have the negotiating leverage that shows up as 144-day debtor days. Concentration risk and working-capital risk are the same risk seen from two angles.

---

6. Valuation and Market Expectations

Onyx is small enough that the standard valuation framework partly breaks. There is no sell-side coverage (analyst_estimates.json is empty), no consensus EPS, no Quality Score, no Fair Value gap from third-party scoring providers — those services do not maintain models on NSE SME microcaps. What is observable is the multiple stack as it stands today.

P/E is undefined because FY2026 net income is negative, so it cannot be used. On normalised FY2025 EPS of ₹2.73, the trailing P/E would be roughly 11.7x — a 60–75% discount to peers.

What the price implies

The stock appears to be discounting at least one of two scenarios:

1. A permanent margin reset. If 7% operating margin is the new normal, fair value sits near book; the current price is approximately fair.
2. An accounting-quality problem. If receivables have to be impaired (the 144-day debtor balance may include questionable receivables), book value itself shrinks, and even 1.05× book is too expensive.

Bear, base, bull frame

The bear case (5% OPM, growth continues) values the company at deep book value because the cash engine is broken. The base case (10% OPM, mid-range historical) approximately validates current price plus a modest 25% upside. The bull case (14% OPM, return toward FY2025 normalised levels) implies a near-double from today. None of these scenarios use peer multiples — they use Onyx's own historical earnings multiple of roughly 11.5x applied to scenario EPS.

---

7. Peer Financial Comparison

The peer set is curated for business-model fit, not market cap — Akums, Cohance, Innova Captab, JB Chemicals, and Senores are the closest economic substitutes that listed Indian investors can actually buy. The mismatch in scale (Onyx is roughly 1% the size of any peer) is intentional — the comparison shows what investors are paying for quality of the financial engine, not for absolute scale.

Onyx's row is the only one with single-digit EBITDA margin and ROCE below 5%. Even Cohance — the lowest-quality peer on ROCE — earns 8.4% on capital and 27% EBITDA margins. The bull thesis here is that Onyx will move up the peer ladder as Unit II ramps and operating leverage kicks in; the bear thesis is that contract-manufacturing economics at sub-₹100 Cr revenue do not support peer-level margins because raw-material buying power, customer pricing power, and fixed-cost absorption all favour scale.

The peer cloud is concentrated at ROCE 14–26% and P/E 30–80x. Onyx is the outlier on both axes — the lowest ROCE and the lowest (normalised) P/E. A normalised P/E of 11.7x on FY2025 EPS is the most defensible argument the bulls have; everything else about the peer comparison favours waiting.

---

8. Shareholder Structure and Float

Worth a note because it changes how the financial signals should be interpreted.

Promoter holding is unchanged at 65.10% — that is the single most positive signal in the entire ownership story. The promoters have not sold a share through the FY2026 margin shock. FII share has collapsed from 8.72% to 1.07% — that is the price the float has paid. Retail public has absorbed almost all of the FII selling. Float is now thin and retail-heavy, which means the equity will overshoot in both directions on any operating data point.

---

9. What to Watch in the Financials

Closing read

The financials confirm three things: (1) Onyx has a real business with a respectable customer book, (2) the IPO genuinely repaired the balance sheet, and (3) the company can grow revenue. They contradict the bull narrative on (1) durability of margins — FY2025's 16.8% OPM was the cycle peak, not a baseline; (2) earnings quality — every rupee of net income has historically delivered roughly twenty paise of CFO; and (3) capital efficiency — ROCE has cratered to 1.1% even though the equity base just got bigger.

The first financial metric to watch is H1 FY2027 operating margin. A print above 10% would point to the FY2026 collapse being transitory, with the equity carrying 25–80% upside to the base/bull scenarios. A print below 5% would suggest the 7% in H2 FY26 was a head fake and that ₹32 (1.05× book) is still not cheap enough.

Web Research — Onyx Biotec (ONYX)

The Bottom Line from the Web

The filings tell you Onyx is a small WHO-GMP contract manufacturer. The internet adds the part the filings bury: the IPO thesis broke 18 months after listing. FY26 audited results (board-approved 14 May 2026) flipped a ₹4.95 Cr FY25 PAT into a ₹0.21 Cr net loss, foreign institutional holding collapsed from 8.72% at listing to 1.07% by Mar 2026, and the post-anchor-lockup tape shows the IPO anchors (ZETA Global Funds, Globalworth Securities) selling steadily into a stock now 48% below issue price.

What Matters Most

The ten findings below are the entire web-research case file ranked by how much each changes the investment view. Material events come first; texture and background later.

1. FY26 swung from profit to loss — the IPO "super-earnings" thesis broke

The IPO reviewer Dilip Davda flagged this risk explicitly pre-IPO: "marked inconsistency in its top lines… highly fluctuating bottom lines raises eyebrows. Based on FY25 super earnings, the issue appears fully priced." That warning has aged perfectly. Source: scanx.trade FY26 results; Chittorgarh IPO review.

2. FII holding has collapsed from 8.72% to 1.07% — 88% exit in 16 months

Trendlyne bulk-deal disclosures itemise the exits: ZETA Series B sold 374,000 shares @ ₹45.12 on 18 Sep 2025; Globalworth sold 176,000 @ ₹51.03 on 11 Aug 2025 and 104,000 @ ₹49.00 on 16 Sep 2025; ZETA Series C sold 154,000 @ ₹32.00 on 30 Mar 2026 and Globalworth sold 190,000 @ ₹32.00 the same day. Smart money exited; the stock cratered through their exit prints. Source: Screener shareholding; Trendlyne bulk deals.

3. Stock is -47.5% below IPO price and -42.9% below 52-week high

The classic SME IPO froth-then-fade tape. The number of shareholders has halved from 1,181 at listing to 586 by Mar 2026 — retail is leaving as fast as institutions. Trendlyne's DVM flags Onyx as "Expensive Valuation, Technically Bearish" with a 27.6/100 momentum score. Source: Business Standard debut coverage; Livemint listing.

4. ~88.9 lakh promoter shares released from lock-up on 29 Nov 2025 — structural overhang

Promoter holding has been frozen at 65.10% since IPO (Naresh Kumar 24.0%, Sanjay Jain 21.5%, Fateh Pal Singh 19.6%) and no promoter pledge has been disclosed. But the lock-up release sets up a structural seller of last resort. Source: MarketScreener corporate events; Chittorgarh promoter detail.

5. Company Secretary resigned 2 months after listing — a yellow card

No public reason was disclosed in the BSE/NSE filing. By itself benign; combined with the financial-controller concentration in #6 below it stops being benign. Source: MarketScreener corporate actions feed; financesaathi DRHP contact-person trail.

6. CEO + CFO + Whole-Time Director are the same person

Combined with three independents on an 8-member board (legal minimum under SEBI for SMEs) and the recent CS turnover, the audit-committee independence picture is borderline at best. SEBI's SME exemption framework allows it; sophisticated allocators won't. Source: Livemint market-stats page; Moneycontrol management.

7. No analyst coverage, no transcripts, no MF ownership — information desert

The implication is decision-grade: there is no consensus, no maintained estimates, no buy-side coverage to anchor a price target. Any allocator buying ONYX is doing primary research alone. Source: Trendlyne coverage page; Livemint stat page.

8. Customer wins post-IPO were operationally real but margin-dilutive

Top-line growth of +10.8% in FY26 confirms the wins are real. But operating margin compressed by ~1,150 bps over the same period — the new business is structurally lower-margin or is loading fixed costs without commensurate price. The Unit-II cephalosporin DPI ramp narrative cannot be both delivering AND collapsing margin; one of those is wrong. Source: MarketScreener events; Zerodha events.

9. ROE / ROCE figures vary 10x across sources — a stale-data problem investors will trip on

For an investor screening on financial portals, the version they land on is luck-of-the-draw. The decision-grade number is Screener's TTM (-0.38% ROE on ₹30.6 book value) because it reflects the most recent reported earnings. Source: Screener ratios; Livemint ratios.

10. No forensic smoking gun — but the questions don't have answers

What the searches couldn't answer are the specialist questions that would matter: receivables aging on the ₹52 Cr "other current assets" balance, the FY25 9x other-income spike composition, related-party-transaction magnitude, the LVP-line commissioning status (₹6.07 Cr of IPO proceeds earmarked), and whether the audit committee includes the CFO. The forensic file is thin not because nothing's there, but because Onyx publishes nothing beyond statutory minimums. Source: NSE filing — Statement of Deviation; Zaubacorp prosecution check (no prosecutions).

Recent News Timeline

What the Specialists Asked

Each specialist phase submitted high-priority research questions; the Parallel searches returned varied results. Below is the per-specialist Q&A with synthesised answers and confidence ratings.

Governance and People Signals

The promoter trio (Sanjay Jain MD, Naresh Kumar WTD, Fateh Pal Singh — not on board) holds 65.10% of equity with zero pledged. Their acquisition cost is essentially zero (NIL / ₹5.17 / ₹5.19 per share per Chittorgarh disclosure), so at ₹32 spot they are vastly in the money even after the 48% IPO drawdown. No promoter has filed an SAST disclosure; promoter holding has been static since listing.

The governance amber flags are concentrated in the executive layer, not the cap table.

Bulk-deal counterparty trail (post-anchor-lockup)

The named bulk-deal sellers and buyers shed light on who was inside the post-IPO bid stack and who is leaving. This is the key insider-tape evidence for the FII collapse from 8.72% to 1.07%.

The Sep-25 prints (≥ ₹45) and the Mar-26 prints (₹32) show the FII exit absorbed a 30% price decline; the anchors did not stop selling as the price fell. Combined with the 8.9M-share lock-up release on 29-Nov-2025, the supply equation through the next 18 months is structurally negative.

Shareholding migration since IPO

Promoters frozen; FIIs gone; DIIs barely moved. The vacated FII share went to public retail — which has also nearly halved by shareholder count (1,181 → 586).

Industry Context

The industry tab carries the full primer. The web layer adds three structural points the filings do not emphasise:

1. Revised Schedule M — the regulatory tailwind narrative. CDSCO's revised Schedule M (initial deadline extended to 31 Dec 2025 for MSME pharma units) forces sub-scale, non-compliant sterile manufacturers to either upgrade or exit. Solan and Baddi are the densest MSME-pharma clusters in India. Onyx is WHO-GMP and operates two compliant units, so the theoretical tailwind is real. What's missing is the magnitude — neither the searched CDSCO Form A filing lists nor industry reports quantified how many Solan/Baddi units have already exited or will. Without that number the tailwind is narrative, not earnings.

2. The peer set Onyx wants to compare itself to is not its real peer set. The RHP cherry-picked Suven Pharmaceuticals (~₹1.05L Cr m-cap, P/E 83.92, RoNW 14.64%) and JB Chemicals (~₹3.48L Cr m-cap, P/E 53.63, RoNW 18.90%) — both 1,800-6,000× larger than Onyx's ₹58 Cr m-cap. The real peer set is Aculife Healthcare (Nirma sub), Otsuka Pharmaceutical India, Albert David, Denis Chem Lab, Parenteral Drugs (India), Akums Drugs & Pharmaceuticals, Innova Captab, Senores Pharmaceuticals. None of these surfaced as named competitor analytics in the seven search files — a research gap. Tracxn lists 878 active competitors in the broader segment with Onyx ranked #387.

3. Cephalosporin DPI is a low-growth global drug class (~3% CAGR). Onyx's Unit II ramp narrative depends on share-taking, not market growth. The cephalosporin global volume base is mature; growth has to come from contract wins against Akums, Innova Captab (Kathua block), Aurobindo, Lupin, Hetero, Aristo — most multiple orders of magnitude larger. The FY26 Galpha and Mankind Prime Labs contracts are credible incremental wins; they are not a category-share story.

Web Watch in One Page

Onyx Biotec is on Watchlist: the bear case carries the structural weight today (FY26 ROCE 1.14%, five-year cumulative free cash flow −₹32.35 Cr, IPO-era governance scaffolding), but the bull has a clean dated inflection in the H1 FY27 print due mid-November 2026 that resolves three of the four variables that matter. The stock sits at ₹32 — almost exactly book value of ₹30.6 — and the live debate is whether 1.05× book is a floor or a ceiling. The five active watches below were chosen to catch evidence that would change the 5-to-10-year view, not just anticipate the next print: the operating recovery test inside Onyx's own filings, the single multi-year thesis-changer (a regulated-market dossier at Unit II), the upstream competitive consolidation risk from Innova Captab's Kathua block, the long-promised but still-unmeasured Schedule M tailwind, and the most-likely modal failure mode (customer in-housing by the top-10 brand-owners that already run their own injectable lines).

Active Monitors

Rank	Watch item	Cadence	Why it matters	What would be detected
1	Onyx half-yearly results, annual report and material corporate filings	Daily	The H1 FY27 print (~13 Nov 2026) and the FY26 Annual Report (~Sep 2026) together resolve three of the four variables that matter — operating margin trajectory, debtor days, cash from operations sign — and for the first time disclose the receivables ageing schedule that decides whether the 1.05× book floor is real or whether stated book impairs from ₹30.6 to ₹22-26.	NSE/BSE board meeting outcomes, half-yearly or annual results with OPM, debtor days, CFO; first-ever trade receivables ageing schedule; top-5/top-10 customer concentration; audit committee composition or statutory auditor changes; LVP own-brand line commissioning; any provision for doubtful debts or qualified audit opinion.
2	Regulated-market accreditation (EU-GMP / USFDA / UK-MHRA) at Unit I or Unit II	Daily	The single multi-year thesis-changer. Driver #4 of the long-term underwriting map — every other variable (margins, working capital, ROCE) is downstream of whether Onyx ever signs the multi-crore capex cheque for a regulated-market dossier. The bull's FY2030 ₹85 fair value depends on this announcement; its absence through FY2028 is the strongest single refutation of the compounder case.	Any filing, inspection, capex commitment or first export shipment under EU-GMP, USFDA, UK-MHRA, ANVISA, PMDA or TGA at the Solan plant; multi-crore capex line tagged for a regulated-market dossier; first export contract or commercial invoice to a regulated market.
3	Innova Captab Kathua cephalosporin block utilisation and regulated-market wins	Daily	Innova's Kathua block — commissioned January 2025 at 23× Onyx revenue scale with EU-GMP credentials Onyx lacks, 30 km away in Baddi — sits upstream of any Schedule M displaced volume. If Innova fills Kathua above 70% with new EU/UK customer wins, the displaced cephalosporin pool consolidates upstream and Onyx's Unit II ramp ceiling drops from 70% to 50% independent of its own execution.	Innova Captab half-yearly or quarterly results, concall transcripts, investor presentations and press releases disclosing Kathua utilisation, new regulated-market customer wins, export revenue trajectory in sterile injectables, or any update on the Sharon Bio-Medicine integration.
4	CDSCO Schedule M enforcement and Solan/Baddi unit closures	Bi-weekly	The Schedule M deadline passed on 31 December 2025 but CDSCO has not yet published district-level closure data. The bull case has anchored on this tailwind for 18 months without a single observable number; a closure count above 200 named units in injectable categories validates the narrative, a count below 50 or a blanket retroactive extension kills one of the two pillars of the bull case. Also catches any inspection finding or WHO-GMP renewal observation at Onyx's own plant.	CDSCO or Himachal Pradesh State Drug Controller publication of Form A district-level closure counts; named exits of unlisted sterile injectable or cephalosporin manufacturers in Solan/Baddi; any retroactive extension or relaxation of Schedule M; any WHO-GMP / EU-GMP / USFDA inspection observation or 483-equivalent finding at the Onyx Solan plant.
5	Customer in-housing — top brand-owner captive injectable capacity additions	Bi-weekly	Failure mode #1: the most likely single cause of the FY26 operating margin collapse continuing into FY27-FY28. Top-10 customers were 71% of FY24 revenue and every name (Sun, Mankind, Hetero, Aristo, Macleods, Reliance Life Sciences) runs captive injectable capacity. Each captive-line capex announcement tightens the Unit I and Unit II ramp ceiling; tenure is not pricing power when the customer can self-supply at the margin.	Concall commentary, NSE/BSE filings, press releases or trade-press reports from Sun Pharma, Mankind, Hetero, Aristo, Macleods, Reliance Life Sciences, FDC, Zuventus or Akums disclosing new captive sterile injectable capacity, ampoule/vial/LVP lines, cephalosporin DPI expansion, lyophilised-vial or PFS capex, or any decision to in-house volume previously outsourced.

Why These Five

The report's verdict frames the next twelve months as bear-with-a-trapdoor: the structural facts (ROCE 1.14%, cumulative five-year FCF of −₹32.35 Cr, governance scaffolding from the IPO window) argue the FY26 reset is not transient, while the H1 FY26 → H2 FY26 sequential OPM bounce from 2.72% to 7.02% keeps a clean dated inflection on the calendar. Monitor 1 is the cleanest catch for that inflection — the H1 FY27 print is the single dated catalyst inside six months and the FY26 Annual Report finally surfaces the receivables ageing detail that decides whether the 1.05× book floor is asset-bracketed or whether ₹52 Cr of "other current assets" carries a real-cash haircut of 15-25%. Monitor 2 is the only watch on this page whose payoff is asymmetric over a five-to-ten-year horizon: a regulated-market dossier filing is the single event that re-rates Onyx from a tangible-asset book-value name into a CDMO compounder candidate, and is the variable the verdict, the long-term thesis page and the moat page all flag as decisive. Monitor 3 tests whether the regulated-grade portion of the Schedule M displaced pool is being absorbed by Innova Kathua before it ever reaches Onyx — the most underweighted threat in the consensus bull case, with the resolution signal landing first (August 2026, ahead of the H1 FY27 print). Monitor 4 puts a quantifiable number on the long-promised Schedule M tailwind that has anchored the bull narrative for 18 months without observable evidence. Monitor 5 watches the modal failure mode — captive in-housing by the same top-10 brand-owners who are also Onyx's customers — and is the one watch that catches a slow-developing bear thesis breaker before it shows up in Onyx's own filings as a top-3 customer drop-out.

Where We Disagree With the Market

The sharpest disagreement is that the ₹32 stock price — almost exactly 1.05× stated book — is not the asset-bracketed floor both sides of the debate treat it as; the ₹52 Cr "other current assets" line that anchors that floor sits on a 144-day receivable book that has never seen a published ageing schedule and a five-year cumulative CFO/NI ratio of 29%, so a 20-30% real-cash impairment is the modal outcome the first time those receivables get audited in granular detail (FY26 AR, ~Sep 2026). Two related disagreements stack on top of that: the Schedule M tailwind that has anchored 18 months of bull narrative accrues upstream to Innova Captab's Kathua block (23× Onyx scale, EU-GMP, 30 km away, commissioned January 2025) before it ever reaches Onyx; and the FII unwind from 8.72% to 1.07% — read as "flow now exhausted" — is better read as the IPO anchors selling continuously at every price from ₹45 to ₹32 on information, not on liquidity. The cleanest single signal that resolves all three is the FY26 Annual Report dispatch (~September 2026), where receivables ageing, top-5 customer concentration and any new provision-for-doubtful-debts line item land in a single document — before the H1 FY27 print the market is currently anchored on.

1. Variant Perception Scorecard

The variant strength score of 62 is constrained, not earned upward — there is a real evidentiary gap between the asset-floor framing and the working-capital reality, but liquidity (ADV ~₹2.4 lakh) means even a clean variant view is not implementable for any institutional book. Consensus clarity sits at 55 because there is no maintained sell-side coverage, no analyst estimate, and the only third-party rating (MarketsMojo's "very attractive" 11-Sep-2025 grade) was issued on FY25 inputs that the FY26 print invalidated; market belief has to be reconstructed from price action, FII flow, retail shareholder count and Stan's synthesised tensions. Evidence strength of 72 reflects strong audited primary data on the cash-conversion gap (5-year cumulative CFO/NI 29%, cumulative FCF -₹32.35 Cr, FY26 CFO -₹1.49 Cr) and on the Innova Kathua competitive overhang, partly offset by the fact that the receivables ageing schedule itself has never been published — we are inferring impairment risk rather than reading it. Time to resolution is four months: the FY26 AR is expected by early September 2026 and is the disclosure where the asset-floor question gets answered first.

2. Consensus Map

The market's beliefs on Onyx have to be triangulated. There is no analyst consensus. What there is: price behaviour relative to book value, FII flow, retail shareholder count, third-party valuation grades, IPO-marketing residue, and the explicit bull/bear tensions Stan crystallised. Each row below names a consensus signal precise enough to be tested.

The two consensus beliefs we are most confident the market actually holds are #1 (the 1.05× book floor — held by both bulls and bears, only the haircut differs) and #5 (the FII unwind narrative — explicitly stated in the catalysts page and confirmed by the bulk-deal trail). #2 and #3 are the IPO-era and post-IPO bull narrative; both still appear in the bull case despite the FY26 print. #6 is the most genuinely speculative consensus signal, but it is the one the bull case leans on hardest for asymmetry.

3. The Disagreement Ledger

Three disagreements survive the materiality, evidence, resolution-path and time-horizon tests. Each one would force a re-rating of the equity in a specific direction, and each has a dated or observable resolution inside 12 months.

Disagreement #1 — stated book is impaired before you arrive. Consensus would say: at 1.05× book, the worst-case downside is bracketed by tangible assets, working capital and the going-concern value of the Solan plant. Our evidence — five years of net income that only converted to cash at 29 paise on the rupee, FY26 CFO turning negative, ₹52 Cr of "other current assets" (55% of total assets) anchored on a 144-day debtor book with no published ageing schedule, and an IPO-year governance scaffold that historically correlates with impairments surfacing late — points to a 20-30% real-cash haircut on the receivable book the first time it is audited in detail. If we are right, the market is paying 1.2-1.5× adjusted book at ₹32, not 1.05×, and the bear's ₹20 target is the asymmetric outcome that the bull case has under-weighted. The cleanest disconfirming signal is the FY26 AR receivables ageing schedule: if >90% of receivables print under 90 days and no provision-for-doubtful-debts line item appears, our disagreement narrows materially.

Disagreement #2 — Schedule M accrues upstream, not to Onyx. Consensus would say: the ~1,000 unlisted Solan/Baddi SMEs that miss the 31-Dec-2025 Schedule M deadline will be forced to exit, freeing up SWFI and cephalosporin DPI volume that compliant CDMOs — including Onyx — pick up. Our evidence — Innova Captab Kathua cephalosporin block commissioned January 2025 at 23× Onyx revenue scale with the EU-GMP credentials Onyx lacks, 30 km away in the same manufacturing belt; Akums' EUR 200M FY25 EU contract; brand-owners (Sun, Mankind, Hetero, Aristo) who already run their own injectable lines and prefer scale CDMOs as second-source — points to a tailwind that is real but consolidates upstream of Onyx. If we are right, the bull's 1.8× book TP requires utilisation lift past 70% that the Innova Kathua ramp specifically prevents, and the structural pillar of the bull case fails before any execution question reaches the operator. The cleanest disconfirming signal is the INNOVACAP H1 FY27 disclosure: if Innova Kathua prints below 60% utilisation through H1 FY28 with no new EU/UK customer wins, the displaced-volume pool has room to spill down to Onyx.

Disagreement #3 — the FII unwind contains a signal, not just flow. Consensus would say: the IPO anchors are gone (FII 8.72% → 1.07%), the remaining float is retail, and the supply equation is structurally cleaner from here. Our evidence — ZETA Global Funds Series B and C and Globalworth Securities (the named IPO anchors) sold continuously across an eight-month window from ₹45.12 (Aug-2025) to ₹32.00 (Mar-2026), absorbing a 30% price decline without bidding; the H1 FY26 collapse on 13-Nov-2025 was met with management silence (no presentation, no investor letter, no concall); the IPO-year other-income spike (9× FY24) that flattered the listing-year P&L is on the same disclosure surface anchors saw — points to information-driven selling, not exhaustion. If we are right, the supply equation is not as clean as the catalysts page suggests, because the next dated event is the residual 31.35% promoter lock-in expiry in November 2027 against a near-zero promoter cost basis. The cleanest disconfirming signal is a clean FY26 AR governance disclosure: Harsh Mahajan removed from the audit committee, related-party transaction magnitude disclosed below 10% threshold with detail, and an LVP own-brand commissioning announcement — all three together would suggest the anchors left for liquidity, not information.

4. Evidence That Changes the Odds

The seven evidence items below are the data that does most of the work in this disagreement. Each one is the kind of fact that a PM should be able to audit in a single follow-up question.

5. How This Gets Resolved

Every resolution signal below is a real disclosure, not a guess. The FY26 Annual Report (Sep 2026) carries three of the seven; the H1 FY27 print (Nov 2026) carries another two. INNOVACAP H1 FY27 (Aug 2026) is the cleanest off-filing signal and lands first.

The seven signals above are not equally decisive. Signal #1 (receivables ageing) is the single most resolving disclosure for disagreement #1. Signal #3 (INNOVACAP Kathua) is the single most resolving disclosure for disagreement #2 — and it lands first, in August 2026. Signal #5 (Onyx Unit I utilisation) and #7 (H1 FY27 three-gate test) jointly test the durable thesis variables the upstream tabs all flag as primary; both arrive in the November 2026 print. Signal #1 is the cleanest single thing to watch. A benign ageing schedule with >90% of receivables under 90 days and no new provision-for-doubtful-debts line would do more to invalidate our top disagreement than any other observable disclosure in the next six months.

6. What Would Make Us Wrong

The cleanest path to being wrong on disagreement #1 is the simplest one: the FY26 receivables ageing schedule prints benign, with over 90% of trade receivables sitting under 90 days, no new provision-for-doubtful-debts line item, and no audit qualification on receivables. If that happens, the entire impairment thesis collapses — the ₹52 Cr "other current assets" line was always going to convert at face value, the bear's ₹26.6 adjusted book is too pessimistic, and the bull case for a 1.5-2.0× book multiple gains genuine support because a clean receivable book is the loud signal that customers are not pushing back on price and the FY26 OPM collapse was indeed fixed-cost under-absorption rather than working-capital impairment in disguise. We have no way of forecasting the ageing distribution before the disclosure; we have only the indirect evidence that points in the other direction, and a benign print would mean that evidence was misread.

The path to being wrong on disagreement #2 is structural: INNOVACAP Kathua prints below 60% utilisation through H1 FY28 with no new EU/UK customer wins. That outcome would mean the regulated-grade displaced volume from Schedule M is not being absorbed upstream by Innova — either because Innova's existing customers are not migrating, or because the regulated-market export pool is shrinking faster than the displaced supply, or because Innova is mid-integration of the recent Sharon acquisition and Kathua is starved for management attention. In any of those scenarios, the volume could spill down to Onyx Unit II, and the bull case structural pillar earns rather than fails. We could also be wrong here on the smaller observation that Onyx's SWFI commodity end already does capture a real share of unlisted-SME displaced volume — that part of the bull narrative is the part we are least confident on, and the next two half-yearly Unit I utilisation prints will test it.

The path to being wrong on disagreement #3 is the most asymmetric. If the FY26 AR resolves the governance scaffolding cleanly — Harsh Mahajan removed from the audit committee, statutory auditor re-appointed without further "casual vacancy" events, related-party transaction magnitude disclosed at line-item granularity below the 10% threshold, an LVP commissioning announcement attached — then the FII unwind was almost certainly a flow event, the anchors left for liquidity reasons that the company has since addressed, and the supply equation is genuinely cleaner from here. That outcome would not invalidate the asset-floor disagreement, but it would substantially de-risk the ownership story and reframe how the underlying anchor selling should be interpreted in the next 18 months.

A broader path to being wrong on all three: management announces a multi-crore capex line for an EU-GMP or USFDA dossier filing at Unit II within FY27, with a credible 12-18 month timeline and a disclosed funding path that is not external equity at sub-book. That single announcement would re-cast Onyx from a tangible-asset book-value name into a real CDMO compounder candidate, and it would dilute every variant view on this page — the asset-floor question becomes irrelevant when the operating engine is being upgraded, the Schedule M tailwind question becomes irrelevant when Onyx joins the regulated-market peer set, and the FII unwind interpretation becomes irrelevant when a new investor base prices the dossier optionality. The probability the report assigns to this outcome is Low (long-term-thesis driver #4 confidence: Low), but Low is not Zero, and a single NSE corporate announcement is the highest-asymmetry refutation event on the calendar.

The first thing to watch is the FY26 Annual Report receivables ageing schedule, due ~September 2026.

Liquidity & Technical

Onyx Biotec trades roughly ₹2.37 lakh of value per day — five trading days of aggressive (20% ADV) participation buys less than 0.04% of the company, so the name is not implementable for any traditional fund. The tape is bearish: price sits 20.5% below the 200-day, near the 52-week low, with a fresh MACD roll-over and elevated realized volatility around the 70th percentile.

Price snapshot

Beta is not estimable — the share has only traded for 18 months and a paired benchmark series did not load (see Section 4 below).

Beta is not estimable — the share has only traded for 18 months and the benchmark series did not load (see Section 4). On the price action, the readout is one-sided: 1-year return is −43.9%, YTD is −20.1%, and the stock sits at the 5.6th percentile of its 52-week range, just over the 52-week low of ₹30.30.

The critical chart: price vs 50-day and 200-day SMA

Price is below the 200-day, by 20.5%. The structure is fully bearish: ₹32 sits underneath the 20-day (₹33.25), 50-day (₹33.43), 100-day (₹34.34) and 200-day (₹40.28), and the 200-day itself has been falling continuously since it first became computable in late 2025. No 50/200 golden or death cross has printed — the 200-day is only available from November 2025 onwards (limited by the post-IPO sample), and the 50-day has been below the 200-day for the entire computable window. This is a primary downtrend, not a pullback in an uptrend.

Relative strength vs benchmark + sector

The benchmark series (INDA, broad India) was not staged in the relative-performance file for this run, and no sector ETF or peer basket is configured for NSE SME microcaps. We therefore have no comparable index curve to plot.

What is unambiguous from the absolute numbers: a Nifty 50 basket returned roughly mid-single-digit positive over the last 12 months in the same window, while ONYX printed −43.9%. On an IPO-anchored rebase (listing price = 100), the stock peaked near 159 in mid-January 2025 and has since drifted to 56 — meaning every buyer above ~₹32 since listing is underwater, and every buyer above ~₹56 (the IPO price) is also offside. The post-IPO "open-window" outperformance has been fully retraced.

Momentum — RSI and MACD

RSI is at 44.6 — neutral but inside the lower half, and it has only briefly tagged 60 since the January-2025 listing peak. Crucially, every RSI bounce toward 55–60 since mid-2025 has been sold; RSI has not closed a single session above 70. The MACD histogram had just flipped positive again in early May, then rolled back below zero on 18 May and accelerated lower on 20 May (−0.20) — that is a fresh near-term sell trigger on top of an already-negative MACD line of −0.23. On the 1–3 month horizon the read is bearish: no momentum divergence supports a higher low; both indicators agree.

Volume, volatility, sponsorship

Average daily volume has collapsed from roughly 165K shares in March 2025 to under 19K shares today — an 88% decline in turnover. The shape is unmistakable: the post-IPO crowd has left, and what remains is a thin retail tape. The biggest volume days mostly show the wrong sign for bulls: 18 September 2025 traded 10.4× average on a −6.6% day, 11 August 2025 traded 6.2× on a −6.7% day. The two largest recent spikes (30 March and 24 March 2026) printed positive but each cleared only ~₹1 crore of value combined — they look like single buyers, not sustained accumulation.

Realized vol sits at 70.6% — between the post-IPO p50 (65%) and p80 (81%) bands. The pattern through Q1 2026 was a regime shift higher: vol broke above 80% from late October 2025 through February 2026, peaking near 94%. It has eased back since but remains elevated. Volume is collapsing while volatility is high — the textbook signature of a name being marked down by a thin order book rather than a fundamental story flowing through institutional bids.

Institutional liquidity panel

ADV and turnover strip

The 60-day ADV (17.8K shares) is more than double the 20-day (7.1K) — the trend is one direction: deteriorating. Annualized turnover of ~24% (using 60d) or under 10% (using 20d) is well below the 50–100% range that supports institutional sizing.

Fund-capacity table

A fund running a 5% position weight is capped at roughly ₹45 lakh AUM at the more aggressive 20% ADV setting, and ₹22.7 lakh at the more conservative 10% ADV — i.e. this name only fits inside an individual brokerage account or a family-office sliver, never inside a real fund.

Liquidation runway

Even a 0.5%-of-market-cap position takes about three months to exit at 20% ADV and over six months at 10% ADV. A 1% position becomes a year-long unwind. There is no scenario in which a fund building this name can rely on the daily tape to exit — exits would require block negotiation or strategic counterparty placement, which a microcap NSE SME with no analyst coverage is unlikely to offer.

Daily-range proxy

The 60-day median daily range is 0.0% in the raw data — every printed OHLC has open = high = low = close, suggesting a single-trade-per-session pattern rather than an active intraday market. The honest read is that intraday execution cost is not measurable from the tape, and any meaningful order will move the print. Treat the displayed price as indicative, not transactable, at size.

Largest 5-day clearable position: about 0.04% of market cap at 20% ADV, or 0.02% at 10% ADV — meaning the issuer-level size that a real fund can move inside a week is two-to-four basis points of the company's float, not anywhere near the 0.5–2.0% sizes shown in the runway table.

Technical scorecard and stance

Stance — bearish on the 3-to-6 month horizon, but bracketed by liquidity. Every dimension scores −1 for a total of −6, which is unusually unanimous and reflects a regime where volume is leaving, volatility is elevated, and price has been making lower highs and lower lows for over a year. The bullish trigger is a daily close above ₹40 (the 200-day SMA) on volume above 25K shares — that would mark the first reclaim of the long-term trend filter since it became computable. The bearish confirmation is a daily close below ₹30 (clearing the 52-week / all-time low at ₹30.30), which would open a path to the IPO-issuance-area gap fill and likely a fresh capitulation move on already-thin volume. Liquidity is the constraint that overrides the tape: even if the technical picture turned constructive, no fund of size can act here on the public market. The implementation verdict is avoid for any institutional book, with retail / specialist participation only possible by accepting weeks-to-months of build time and a similar exit window. Watchlist status is appropriate only if a structural catalyst (capacity addition, regulated-market export approval) re-rates fundamentals and the float deepens through follow-on issuance.